CONFIDENTIAL
GlaxoSmithKline Group ofCompanies BRF117277
1Division: World Wide Development
Retention Category: GRS019
Information Type: Reporting and Analy sisPlan
Compound Number: GSK2118436, GSK1120212 / [STUDY_ID_REMOVED]
Effective Date: 05-Mar-2018
Description :This document details the reporting and analy sisplan for BRF117277, a
non-randomized, multi -center Phase II stud yto evaluate efficacy and safety of combined
therapy  with dabrafenib and trametinib in patients with BRAF mutation -positive
melanoma with brain met astases.  Four cohorts based on typeof mutation, ECOG
performance score, presence of symptoms and prior local therap yof brain lesions will be
treated.  The primary objective is to assess the intracranial response rate in subjects with
locally confirmed B RAF V600E -mutation positive melanoma that has metastasized to the
brain without sy mptoms and have not undergone prior local therap yfor brain metastases,
ECOG score of 0 -1(Cohort A).Other secondary objectives include intracranial,
extracranial, and overa llresponse in all cohorts, progression -freeand overall survival,
duration of intracranial, extracranial, and overall response inallcohorts, and the
incidence and severity ofadverse events bycohort.
Subject: Oncology ,Reporting and Anal ysis Plan, melanoma, brain metastases, BRAF
inhibitor, BRAF V600E mutation, BRAF V600K mutation, BRAF V600R mutation, 
BRAF V600D mutation, intracranial
Author’s Name, Title andFunctional Area:  
Copy right 2017 the GlaxoSmithKline group of companies. All rights reserved.
Unauthorised copy ingor use of this information is prohibited.
Title:
 Reporting and Analy sisPlan for BRF117277 :A Phase II,
Open -Label, Multicentre Study of Dabrafenib plus Trametinib in
Subjects with BRAF Mutation -Positive Melanoma that has
Metastasized to the Brain (Amendment 1)

CONFIDENTIAL
GlaxoSmithKline Group ofCompanies BRF117277
2Approved Via E-mail by:
Email approval on file
3CONFIDENTIAL
GlaxoSmithKline Group ofCompanies BRF117277
Revision Chronology
Date Version
2015 -FEB-10 Original
2017 -FEB-23 Amendment No. 1
2018 -MAR -05 Amendment No. 2
4CONFIDENTIAL
GlaxoSmithKline Group ofCompanies BRF117277
1)Minor correction to typographical errors throughout the document.
2)Title page: Updated description about study objective - to assess the intracranial
response rate in subjects with locally confirmed BRAF V600E -mutation positive
melanoma.
3)
Section 2: Updated study objectives to be consistent with the study protocol
amendment No.5 –1. Primary endpoint amended to allow for locally confirmed BRAF
V600E (followed by central confirmation as with all other cohorts) and 2. Secondary
endpoint number 9: OS changed from 5to 3year.
4)Section 3: Updated Study design - Cohort A patient population updated to allow for
locally confirmed BRAF V600E (followed by central confirmation as with all other 
cohorts) and definition of study closure updated from “where all subjects still in
follow uphave had at least 5 yearsfollow up…” to “where all subjects still in follow
up have had at least 3yearsfollow up…”.
5)Updated Protocol reference information from “Protocol Amendment 01, dated 27
April 2014 GlaxoSimthKline Document Number ( 2013N168168437_01 )” to 
“Protocol Amendment 05, dated 13 July 2016 GlaxoSimthKline Document Number 
(2013N168437_07)”.
6)Section 4and 4.2: reference to 5year survival changed to 3.
7) Section 5.1: To clarify the significance level at the time of primary analy sis,added
“and the primary endpoint test in the primary analy siswill be performed at 5% level”.
8)
9)Added section 9.2.15 to clarify how to appl yanalysis cut -off date.
10)
Section 10.3, 10.5 and 10.6: Updated the drug dictionary reference from “GSK Drug
coding dictionary ”to “WHODrug coding dictionary ”.
11)Section 11.1: added “As a window of 7 daysis allowed for scheduling, 7 weeks (or
49 day s)will be used for analy sis”to clarify thestable disease criteria.
12)Asindependent reviewer -
assessment has been done, removed all the hy pothetical
wording (“Ifdone”) removed.

5CONFIDENTIAL
GlaxoSmithKline Group ofCompanies BRF117277
13)Section 11.2: Added detailed derivation rules forthedate oflastcontact.
14) Section 11.2: Added “The duration ofintracranial, extracranial, andoverall response 
per independent reviewer -assessment willalsobesummarized. Figures andlistings of
duration of independent reviewer -assessed response will also be provided.”.
15)Section 11.2: Added “Frequency of patients with PFS events will be presented and
also separately bytypes of PFS event, i.e. progression or death.”.
16)Section 11.2: Added “PFS per independent reviewer -assessment will be summarized.
Afigure andlisting ofprogression -freesurvival time per independent reviewer will
also be provided.”
17) Section 12.3: “Summaries of exposure- adjusted incidence rates will be produced for
each AE of special interest” deleted.
18) Section 12.3: Updated the list of adverse event of special interest following 
MedDRA19.1.
19)Section 12.7.1: “Atrellis display of LFT shifts from baseline to maximum values will
be provided.” Deleted.
20)Section 12.8: Deleted analy sisabout neurological exam as the data is not available to
produce these display s.
21)Section 14.1: Modify the Table of Contents for data display sto be consistent with the
updated AESI and the required analy sisper team’s discussion and agreement. To be
specific, Thefollowing changes have been made,
a.Updated all AESI related display sto be consistent with the latest MedDRA
19.1.
b.Removed “2.0061 Kaplan -Meier Estimates of Overall Survival at 3 Years by
Cohort” from the list of display sfor primary analysis.
c.Added “2.0061 Kaplan -Meier Estimates of Overall Survival at 3Years by
Cohort” to the list of display sfor end of study analysis.
d.Removed all the display sfor Summaries of exposure -adjusted incidence rates
for each AE of special interest.
e.Updated “1.1220 Summary ofStudy Treatment Status by Cohort” to “1.1220
Summary ofStudy Treatment Status for Trametinib by Cohort”.
f.Added “1.1221 Summary ofStudy Treatment Status for Dabrafenib by
Cohort”.
g.Removed “3.9020 Summary of Neurological Examinations by Cohort” and 
“30.0340 Listing of Neurological Assessments”.
h.Removed “12.0080 Trellis Display of Patient Profiles of LFT Results by
Cohort”.
CONFIDENTIA L
BRF117277
2TABLE OF CONTENTS
PAGE
ABBREVIATIONS ......................................................................................................................... 4
1.INTRODUCTION ................................................................................................................... 6
2.STUDY OBJECTIVES AND ENDPOINTS ........................................................................ 6
2.1. Statistical Hypotheses ............................................................................................. 9
3.STUDY DESIGN ................................................................................................................... 9
4.PLANNED ANALYSES ...................................................................................................... 10
4.1. Interim Analyses ..................................................................................................... 10
4.2. Final Analyses ........................................................................................................ 10
5.SAMPLE SIZE CONSIDERATIONS ..................................................................................... 11
5.1. Sample Size Assumptions .................................................................................... 11
5.2. Sample Si ze Sensitivity ......................................................................................... 11
5.3. Sample Size Re-estimation .................................................................................. 11
6.ANALYSIS POPULATIONS .............................................................................................. 12
6.1. All Treated Populations ......................................................................................... 12
6.2. All Enrolled .............................................................................................................. 12
6.3. Safety Population ................................................................................................... 12
6.4. Analysis Datasets ................................................................................................... 12
7.TREATMENT COMPARISONS ........................................................................................ 12
7.1. Data Display Treatment ............................................................................................. 13
8.GENERAL CONSIDERATIONS FOR DATA ANALYSES ............................................ 13
8.1. Multicenter Studies ................................................................ ................................ 14
8.2. Other Strata and Covariates ................................................................................. 14
8.3. Examination ofSubgroups .................................................................................... 14
8.4. Multiple Comparisons and Multiplicity ................................................................. 14
9.DATA HANDLING CONVENTIONS ................................................................................. 15
9.1. Premature Withdrawal andMissing Data ........................................................... 15
9.2. Derived and Transformed Data ............................................................................ 15
9.2.1. Reference dates .................................................................................... 15
9.2.2. Study Day for Safety Measures .......................................................... 16
9.2.3. Study Day for Efficacy .......................................................................... 16
9.2.4. Duration and Elapsed Time ................................................................. 16
9.2.5. Imputation of Partial Dates ................................................................... 17
9.2.6. Imputation of Missing Exposure End Dates ...................................... 23
9.2.7. Baseline Definition ................................................................................ 23
9.2.8. Change from baseline .......................................................................... 24
9.2.9. Multiple Assessments ........................................................................... 24
9.2.10. Actual Treatment ................................................................................... 24
9.2.11. Extended Loss to Follow -up or Extended Time without an
Adequate Assessment .......................................................................... 24
9.2.12. Date Associated with Response ......................................................... 25
CONFIDENTIA L
BRF117277
39.2.13. Cardiac Scan Modalities (ECHO/MUGA) .......................................... 25
9.2.14. Derived and Transformed Variables ................................................... 25
9.2.15. Cut-off date ............................................................................................ 27
9.3. Study Time Periods ................................................................................................ 27
9.3.1. TimeinRelation to Treatment ............................................................. 27
9.3.2. Study Time Periods for Concomitant Medications and
Blood and Blood Supportive Care Products ...................................... 28
9.4. Values of Potential Clinical Importance ............................................................... 29
9.4.1. Laboratory Parameters ......................................................................... 29
9.4.2. ECG Parameters: .................................................................................. 29
9.4.3. Vital Signs .............................................................................................. 30
9.4.4. Left Ventricular Ejection Fraction ........................................................ 31
10.STUDY POPULATION ....................................................................................................... 32
10.1. Disposition of Subjects .......................................................................................... 32
10.2. Protocol Deviations ................................................................................................ 32
10.3. Demographic and Baseline Characteristics ....................................................... 32
10.4. Treatment Compliance .......................................................................................... 33
10.5. Concomitant Medications ...................................................................................... 33
34
11.EFFICACY ............................................................................................................................ 34
11.1. Primary Efficacy Analysis ...................................................................................... 35
11.2. Secondary Efficacy Analyses ............................................................................... 36
11.3. Other Efficacy Analyses ........................................................................................ 42
12.SAFETY ANALYSES .......................................................................................................... 42
12.1. Extent of Exposure ................................................................................................. 42
12.2. Adverse Events ...................................................................................................... 43
12.3. Adverse Events of Special Interest ...................................................................... 44
12.4. Deaths and Serious Adverse Events ................................................................... 45
12.5. Adverse Events Leading to Discontinuation of Study Treatment and
Dose Modifications ................................................................................................. 46
12.6. Pregnancies ............................................................................................................ 46
12.7. Clinical Laboratory Evaluations ............................................................................ 46
12.7.1. Analyses of Liver Function Tests ........................................................ 47
12.8. Other Safety Measures ......................................................................................... 48
50
13.REFERENCES .................................................................................................................... 51
14.ATTACHMENTS ................................................................................................................. 52
14.1. Table of Contents for Data Display Specifications ............................................ 52
14.1.1. Data Display Deliverables .................................................................... 62
14.1.2. Outputs for the Interim Analysis .......................................................... 74
14.2. Data Display Specifications .................................................................................. 76

CONFIDENTIA L
BRF117277
4Abbreviations
AE Adverse Event
ATC Anatomical Therapeutic Chemical
ATS All Treated Subjects
CI Confidence Interval
CR Complete Response
CTCAE Common Terminology Criteria for Adverse Events 
CTX Anti-cancer Therapy  Dataset
DIR Duration of Intracranial Response
DER Duration ofExtracranial Response
DOR Duration of Overall Response
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Easter Cooperative Oncology Group
eCRF Electronic Case Report Form
ER Extracranial Response
GSK GlaxoSmithKline
IDMC Independent Data Review Committee
IDSL Integrated Data Standards Library
IR Intracranial Response
LDH Lactate Dehy drogenase
LLN Lower L imit of Normal
LVEF Left Ventricular Ejection Fraction
MedDRA Medical Dictionary for Medical Affairs
NCI National Cancer Institutes
OR Overall Response
OS Overall Survival
PD Progressive Disease
PFS Progression -freeSurvival
PR Partial Response
PT Preferred Term
RAP Reporting and Analy sisPlan
RECI ST Response Evaluation Criteria in Solid Tumors
SAE Serious Adverse Event
SD Stable Disease
SOC System Organ Class
SRT Safety Review Team
ULN Upper Limit of Normal
CONFIDENTIA L
BRF117277
5Trademark Information
Trademarks of the GlaxoSmithKline 
group of companies
Mekinist
TafinlarTrademarks not owned by the 
GlaxoSmithKline group of companies
SAS
CONFIDENTIA L
BRF117277
61. INTRODUCTION
This reporting and analy sisplan (RAP) details all planned analy sesrequired for a Clinical
Study Report of stud yBRF117277. This is a phase IIstudy to evaluate the efficacy and
safet y ofBRF117277 using a non-randomized, open -label, multiple cohort design.
For further information on the study design, see Protocol Amendment 05, dated 13 July
2017, GlaxoSimthKline Document
Number (2013N168437_07).
The content of this RAP is based on the SOP and Information for Authors: Reporting and
Analy sisPlans  effective 23 March 2011.
All decisions regarding final analy sis,as defined in this RAP document, have been made
prior to Database Freeze o f the study data. Interim analy sesare detailed within Section
4.1,where applicable.
2. STUDY OBJECTIVES ANDENDPOINTS
Objectives Endpoints
Primary
Toassess theintracranial response (IR) ofsubjects
with locally confirm edBRAF V600E -mutation
positive melanoma thathasmetastasized tothe
brain without symptoms andhave notundergone
prior local therapy forbrain metastases, ECOG
score of0-1(Cohort A).IRisdefined astheproportion ofsubjects
with aconfirmed intracranial complete
response (CR) orpartial response (PR) asper
investigator assessment using modified
RECIST 1.1guidelines.
Secondary
1.Toassess cohort BforIRofsubjects withlocally
confirmed BRAF V600E cutaneous melanoma
with metastases tothebrain confirm edbyMRI,
asymptomatic with prior local therapy forbrain
metastases; ECOG score of0-1.
2.Toassess cohort CforIRofsubjects withlocally
confirmed BRAF V600 D/K/R cutaneous
melanoma with metastases tothebrain confirmed
byMRI, asymptomatic, with orwithout prior
local therapy; ECOG score of0-1.
3.Toassess cohort DforIRofsubjects with locally
confirmed BRAF V600 D/E/K/R cutaneous
melanoma with metastases tothebrain confirmed
byMRI, symptomatic; with orwithout prior local
therapy; ECOG score of0-2.IRisdefined asthepercentage ofsubjects
with aconfirmed intracranial complete
response (CR) orpartial response (PR) asper
investigator assessment using modified
RECIST 1.1guidelines.

CONFIDENTIA L
BRF117277
7Objectives Endpoints
4.Toassess Cohorts A,B,CandDforDisease
Control forintracranial, extracranial andoverall
response (IDC, EDC andODC respectively)
5.Toassess Cohorts A,B,CandDforextracranial
response rate(ER)
6.Toassess Cohorts A,B,CandDforoverall
response rate(OR)
7.Toassess Cohorts A,B,CandDforduration of
response forintracranial, extracranial andoverall
response (DIR, DER andDOR respectively)
8.Toassess Cohorts A,B,CandDforprogression -
freesurvival (PFS)Intracranial Disease Control (IDC) is
defined asCR+PR+SD forintracranial
disease
Extracranial Disease Control (EDC) is
defined asCR+PR+SD forextracranial
disease
Overall Disease Control (ODC) is
defined asCR+PR+SD for overall
disease
Extracranial response (ER), defined as
thepercentage ofsubjects with abest
extracranial response ofaconfirm edCR
orPRbyinvestigator assessment using
modified RECIST 1.1
Overall response (OR), defined asthe
percentage ofsubjects with abestoverall
confirmed response ofCRorPRby
investigator assessment
Duration ofintracranial, extracranial and
overall response (DIR, DER andDOR),
defined asthetimefrom first
documented evidence ofCRorPRuntil
time offirstdocumented intracranial,
extracranial, oroverall disease
progression.
PFS, defined astheinterval betw eenfirst
dose andtheearliest date ofdisease
progression ordeath duetoanycause
CONFIDENTIA L
BRF117277
8Objectives Endpoints
9.Toassess CCohorts A,B,CandDforoverall
survival (OS)andlong-term (particularly 5-
year)OSOverall survival (OS), defined asthe
time from firstdose until death dueto
anycause
10.  To assess Cohorts A,B,CandDtocharacterize
thesafety ofdabrafenib andtrametinib
combination therapy.Assessment ofsafety ofdabrafenib and
trametinib measured bythefrequency and
severity ofadverse events, skin assessments,
laboratory abnormalities, vital signs, and
assessment data(12-leadelectrocardiograms
(ECG), echocardiograms, andclinical
monitoring/observation including neurological
examination)

CONFIDENTIA L
BRF117277
92.1. Statistical Hypotheses
The primary efficacy objective of this study is to assess the intracranial response (IR) rate
inBRAF V600E mutation positive subjects assessed by Investigators using modified
RECI ST1.1 criteria for Cohort A:
Cohort A: 75 Subjects who are treatment -naive for brain metastases,
asymptomatic and stable on corticosteroids.
The study is des igned to provide evidence to support the null hypothesis, H0:IRR≤ 35%
or to reject it in favor of thealternative hypothesis, HA:IRR ≥ 50% for BRAF V600E
mutation -positive subjects in Cohort A.
This hypothesis willbetested using a one- sided test for superiorit ywith α=0.05. There
will be no other testing; therefore, there will be no adjustment of the TypeI error for
multiple testing.
3. STUDY DESIGN
This study will evaluate the safety andefficacy of 4 cohorts, each receiving the same
treatment. Cohort A:Seventy -five subjects with locally confirmed BRAF V600E
cutaneous melanoma with metastases to the brain confirmed byMRI,asymptomatic,
without prior local (brain) therapy and ECOG score of 0 -1.Cohort B: Fifteen subjects
with locally confirmed BRAF V600E cutaneous melanoma with metastases to the brain 
confirmed byMRI,asymptomatic, with prior local (brain) therapy  and ECOG score of 0 -
1. Cohort C: Up to fifteen subjects with locally confirmed BRAF V600D/K/R cutaneous
melanoma with metastases to the brain confirmed by MRI , asymptomatic, with or
without prior local (brain) therapy and ECOG score of 0 -1.Cohort D:Fifteen subjects
with locally confirmed BRAF V600D/E/K or R cutaneous melanoma with metastases to
the brain confirmed byMRI,symptomatic, with or without prior local (brain) therapy and
ECOG score of 0 -2.
Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until
evidence of disease progression, death, or unacceptable toxicity .Subjects will be
required to meet all eligibility criteria and return to clinic on a monthly basis for clinical, 
skin and laboratory assessments. Intracranial and extracranial disease will be assessed at
baseline, Week 4, Week 8, andevery 8 weeks thereafter.  After Week 40,disease
assessments may be performed every 12 weeks. Response to treatment will be evaluated
using modified Response Evaluation Criteria in Solid Tumors (RECI ST)version 1.1.
AnIndependent Data Monitoring Committee (IDMC) will be used in this study .
Protocol -specified guidelines for dose adjustments, interruptions and discontinuation due
to adverse events are provided in Protocol Amendment 05, dated 13 July 2016
GlaxoSimthKline Document Number (2013N168437_07). After discontinuation of study
treatment , subjects will remain in the study for follow -upassessments including monthly
skin assessments up to 6 months and updates on anti-cancer treatment until death.
Subjects who have not died, but are no longer being followed for disease progression or
survival are considered to have withdrawn from the study .Thestudy will be completed
when either all subjects are dead or lost to follow -up,or all subjects still in follow -up
CONFIDENTIA L
BRF117277
10have had at least 3years follow -up from the date of first dose of stud ytreatment,
whichever is earlier.
4. PLANNED ANAL YSES
In line with I CH E9 [European Medicines Evaluation Agency (CPMP/I CH/3633/96) ],
membership of the analysis populations will be determined using th e definitions in 
Section 6of this RAP.
The primary efficacy analy sis willbeperformed when allsubjects inCohort A have had
the opportunity for three (3) post baseline disease assessments. Atthis time the final
intracranial response analysis will be performed and an interim anal ysis of PFS and OS
will be provided. The final analy sisof PFS, OS, and safety will occur after allsubjects
have died or are otherwise lost to follow -upor 3years from the first dose of study
treatment, whichever is soonest.
4.1. Interim Analyses
There isaformal interim analy sisfor futility only with a statistical decision rule in this
trial. For Cohort A,an interim analy sis will take place after 22 subjects have been treated
and had the opportunity  foratleast twodisease assessments. Theresponses used inthis
interim analy sisdo not have to be confirmed.   At least 8 of the 22 subjects must have an
IR (intracranial CR or PR) for the trial to continue.  If 7 or fewer subjects have an IR, this
is evidence that the null hypothesis is true. If accrual is not complete at the time of the
interim analy sis,it will continue during this analy sis.
An IDMC will review accumulating safety and efficacy  data, including the resul tsof the
interim review of safety and efficacy and make recommendations to continue, modify , or
terminate the study ifthere areconcerns regarding safety .The specific responsibilities,
review schedules and composition of the IDMCwill be outlined in a separate document,
the IDMC charter. The IDMC will review the study results at least once for efficacy and
futility .  Additional routine reviews of safet ydata will be scheduled as needed.
4.2. Final Analyses
The primary analyses will be performed after allsubjects in Cohort A have had the
opportunity for three (3) post-baseline disease assessments. This analy siswill be
performed after the database is frozen. After allsubjects have died or are otherwise lost to
follow -upor 3yearsfrom the first dose of study treatment, whichever is soonest, the End
of Study analy siswill be performed on the total cumulated safet ydata and overall
survival. This analy siswill be performed after the End of Study database is frozen. The
display s that will be included in thisanaly sisare listed in Section 14.1.1 .
CONFIDENTIA L
BRF117277
115. SAMPLE SIZE CONSIDERA TIONS
5.1. Sample Size Assumptions
The sample size is based on the hypothesized improvement in intracranial response over
study GSK BRF113929 (BREAK- MB) in Cohort A.  A 35% intracranial response (IR) is
not clinically significant over existing therapies. An intracranial response (IR)of 50% is
of clinical significance.
For the primary endpoint cohort (A),75BRAF V600E mutation positive subjects will be
enrolled. At the time of the primary efficacy analy sis,at least 33 subjects with an IR
(44%) are required to establish that the evidence does not support the null hypothesis.
The sample size is based on a one- sided superiority test of binomial proportions with an
overall TypeI error rate 0.05 incorporating an interim analy siswith the spending function
proposed byLan,(1983) with Pocock Boundary . The null hypothesis in Cohort A will be
tested assuming IR of 35% against an IR of 50% using a one-sided test for superiority
with α=0.05 and power=82%. There will be no other testing; therefore, there will be no
adjustment of the TypeI error for multiple testing and the primary endpoint test i n the
primary analy siswill be performed at 5% level.
5.2. Sample Size Sensitivity
Table 1shows statistical power for the test of the null hypothesis in Cohort A under the
assumed IRof 35%.   It includes statistical power for scenarios where the alternative
response rate is lower and higher.   All statistical power calculations assume 75 BRAF
V600E mutation positive subjects in the Cohort A All Treated Subjects population.
Table 1 Statistical PowerScenarios with 75 BRA FV600E Mutation Positive
Subjects in Cohort A
IR Statistical Power
40% 22.9%
45% 53.8%
50% 82.1%
55% 96.2%
5.3. Sample Size Re-estimation
Sample size re-estimation is not planned for this study .
12CONFIDENTIA L
BRF117277
6. ANAL YSIS POPULATIONS
6.1. AllTreated Populations
All subjects who receive at least one dose of study medication will comprise the All
Treated subjects (ATS) population.
The V600E population will comprise all BRAF V600E mutation positive subjects in the 
ATS population.
The V600D/K/R population will comprise all BRAF V600D/K/R mutation positive 
subjects in the ATS population.
6.2. AllEnrolled
The All Enrolled population comprises all subjects who were enrolled regardless of
whether they had a dose of study treatment.
6.3. Safet yPopulation
The safety population is the ATS population.
6.4. AnalysisDatasets
Primary efficacy analyses will be based on investigator -assessed results in the ATS
population. Ifindependent review of efficacy is done, those analysis results will be
secondary .
Safety analyses will use the ATS population.
The V600D/K/R population, defined above and identified in the study protocol as a
population tobeused to report on secondary efficacy endpoints by cohorts, will not be 
used.   This change was made to accommodate the small sample size in Cohorts B-D (15
subjects per cohort). Analy sesof subgroups of 15 subjects would not generally be
meaningful and are not specified a priori .
7. TREA TMENT COMPA RISONS
There arenotreatment comparisons. The primary objective will be supported by testing
the null hypothesis in Cohort A. The four cohorts will not be compared statistically for
anyendpoint.
13CONFIDENTIA L
BRF117277
7.1. Data Display Treatment
The following treatment descriptors will be used on all applicable display s.  Results will
be reported bycohort.
Treatment Group Data Display Order of Treatment
Groups
Code Description
A Dabrafenib+Trametinib Dabrafenib+Trametinib n/a
8. GENERA LCONSIDERA TIONS FOR DATAANAL YSES
Analy sisdatasets will be created according to CDISC/ADaM standards, and data will be
listed and summarized according to GSK Integrated Data Standards Library (IDSL)
reporting standards. Formatting for dates, times, and decimal places will follow GSK
standards except where specified.
The currently supported versions of SAS, S- Plus software, and TSCG (for figures) will
be used to perform all data analy ses,generate tables, figures, and listings.
Alldata in the database will be presented in by-subject data listings.
All data up to the time of study completion orwithdrawal from the study will be included
in the analy sis,regardless of duration of treatment.
As the duration of treatment for agiven subject will depend on efficacy and tolerability ,
the duration of follow-up will vary between subjects. Consequently ,there will be no
imputation for missing data.
Usethecenter IDinsummaries andlistings, as needed. Summary tables and listings will 
NOT generally be separated by investigator nor will investigator be a factor in any
statistical models.  Unless otherwise stated, all listings will be sorted bycenter I D,
subject number, cohort, then byvisit date.
Unless otherwise stated, continuous variables willbesummarized with n,mean, median,
standard deviation, minimum andmaximum, andcategorical variables willbe 
summarized with frequency counts and percentages.
Summaries will be produced bycohort.
All laboratory data will be presented in GSK’s standard units for reporting.
”Worst -case post-baseline” values will be derived using scheduled and unscheduled visits.
Planned times relative to study drug dosing will be used in all tables and summary figures.
14CONFIDENTIA L
BRF117277
Generally , only pre-specified planned times will be used in the summaries, statistical
analy sesand calculations of an yderived parameters andunscheduled readings willbe
listed. However, both unscheduled and scheduled readings will be included in the 
computation of maximum toxicity and in post -baseline shifts display s forlabsandinany
listing.
Assessment windows will not be defined for the purpose of classify ingmeasurements
obtained outside scheduled assessment times.
Deviations from the analyses inthe RAP will be identified in the CSR.
8.1. Multicenter Studies
Data from allparticipating centers willbepooled prior toanaly sis.Itis anticipated that
subject accrual will be spread thinly across centers and summaries of data by center 
would be unlikely tobeinformative andwill not, therefore, beprovided. However, a
summary of treated subjects bycenter will be produced.
8.2. Other Strata andCovariates
In all efficacy analy ses, there is no stratification. There are no formal plans for
investigating anycovariates.
8.3. Examination ofSubgroups
There are no formal plans for examining subgroups except reporting adverse events by
sex and age groups (<65 years old and 65 yearsold).
8.4. Multiple Comparisons andMultiplicity
The Type Ierror rate will not be adjusted for multiplicity  in secondary  or supporting
analy ses.
15CONFIDENTIA L
BRF117277
9. DATAHANDLING CONVENTIONS
9.1. Premature Withdrawal andMissing Data
Because study treatment is dependent on the study endpoints (e.g., progression), the
length of treatment for each subject will depend on the efficacy andtoxicity of the 
treatment, so the duration of treatment will vary across subjects. Similarly the duration of
follow upwill also vary .All available time-to-event data will be analy zedusing suitable
statistical methods; subjects with shorter treatment andfollow -updue to the natural
history of their disease or medical necessities of the treatment of their disease will not be
considered to have missing time -to-event data. For endpoints which determine the
percentage of responders, subjects with unknown or missing best overall response will be
assumed to be non -responders, and will be included in the denominator when calculating
the percentages.
In the event that the study is terminated , all available data will be listed and a review 
carried out by thestudy team to assess which statistical analy ses are still considered
appropriate.
Missing data occurs when any requested data is not provided, leading to blank fields on 
the collection in strument. These data will be indicated by the use of a “blank” in subject
listing display s.Answers such as “Not applicable” and “Not evaluable” are not
considered to be missing data and should be displayed as such.
Subjects with the designation of treatment relationship for adverse events (AE)s and 
serious adverse events (SAEs) missing willhave theworst case assumed to impute the
relationship: if relationship to study treatment ismissing itwillbeassumed tobe“Yes”.
There willbe no other impu tation formissing data other than what’s described in Section
9.2forpartial dates and for missing exposure end dates.
9.2. Deriv edandTransformed Data
The following sections provide a general description of the derived and transformed
variables used to describe and analy zethe data. Separate analy sis dataset specifications
provide full details on all data derivations and transformations including descriptions of
core standard algorithms and standard Oncology algorithms. The analy sisdataset
specifications will clearly communicate the content and source of the datasets supporting
the statistical analy ses.
9.2.1. Reference dates
There arethree reference dates:
Because age is an eligibility requirement, the reference date for age is the date of 
screening.
The safety reference date is the treatment start date, and will be used to calculate study
dayfor safet ymeasures.
16CONFIDENTIA L
BRF117277
The efficacy reference date is the treatment start date an d will be used to calculate study  
dayfor efficacy measures and baseline characteristics (such as time since initial 
diagnosis), as well as efficacy durations.
9.2.2. Study Day for Safety Measures
Ifthedate ofinterest occurs on or after thesafet yreference date then the safety study day
will be calculated as (date of interest - safety reference date) + 1.If the date of interest
occurs before the safety reference date then the safety study daywill be calculated as
(date of interest –safety reference date). There is no safet ystudy day0.
9.2.3. Study  Day  forEfficacy
If the date of interest occurs on or after the efficacy reference date then efficacy study day
will be calculated as (date of interest -efficacy reference date) + 1. If the date of interest
occurs prior to the efficacy reference date then efficacy study daywill be calculated as
(date of interest –efficacy reference date). There isno efficacy study day0.
9.2.4. Duration and Elapsed Time
Durations (e.g., the duration of an adverse event, duration of exposure, etc.) are
calculated as the stop date minus the start date plus one.
For elapsed time (e.g., thetime since initial diagnosis):
Ifthe reference date is on or after the event date, then the elapsed time is the
reference date minus the event dat e + 1.
Ifthe reference date is before the event date then the elapsed time is the reference
date minus the event date.
When reporting time to event (TTE) durations (progression -free survival, duration of
intracranial, extracranial, and overall response, overall survival) in months, divide the
number of day sby30.4375; to report in weeks divide the number of daysby7; to report
inyears divide the number of daysby365.25. These algorithms for time to event return
decimal numbers, and ignore the actual n umbers of day sin the months or yearsbetween
start date and stop date. The "year"used in these algorithms is 365.25 day s long, and the
"month" is one twelfth of that year.
For converting all other durations (e.g., duration ofadverse events, duration of exposure,
age) to weeks, months or years usethefollowing:
To report the duration in weeks, divide the number of day sby7.
To report the duration in months use:
(YEAR(stopdate +1) -YEAR(startdate)) *12 +(MONTH(stopdate +1) -
month(startdate) -1) + (DAY(stopdate +1) >= DAY(startdate))
To report the duration in years use:
17CONFIDENTIA L
BRF117277
intck('y ear', startdate, stopdate + 1) - (month(stopdate + 1) < month(startdate) or
(month(stopdate + 1) = month(startdate) and day(stopdate + 1) < day(startdate)))
Thealgorithms above for age and duration return whole numbers for months and years,
accurately  accounting for the actual numbers of days in the months or years between the
start date and the stop date.
9.2.5. Imputation of Partial Dates
Imputed partial dates will not be used to derive study day,duration (e.g., duration of
adverse events), or elapsed time variables. In addition, imputed dates are not used for
deriving the last contact date in overall survival analy sisdataset.
With the exception of new anti-cancer start date onthe Oncology time to event anal ysis
dataset and exposure end date on the Exposure analy sis dataset, imputed dates will also
not be stored on datasets.
Imputed dates will not be display ed in listings. However, where necessary ,display
macros may impute dates as temporary variables for the purpose of sorting data in listings 
only.In addition partial dates may beimputed forspecific analy sispurposes as outlined
below.
The partial date imputation will follow ADaM conventions. The ADaM approach is to
populate the numeric date variables with the imputed date and add a flag variable to the 
dataset that indicates the level of imputation.
The flag variable can contain the values: blank, 'D', 'M', 'Y'.
blank: indicates that no imputation was done
D='Day': indicates that the day portion of the date is imputed
M='Month': indicates that the month and day portions of the date are imputed 
Y='Year': indicates that the entire date (year,month, and day)is imputed
Example of Date Variables:
XYZD_ -character date variable
XYZDT -numeric date variable
XYZDTFL -flag variable
Details on imputing partial dates for specific datasets follow.
Adverse Events (AE):
Imputations intheadverse events dataset are used for slotting events to the appropriate
study time periods and for sorting in data listings.
Dataset Date Missing 
ElementRule
18CONFIDENTIA L
BRF117277
Dataset Date Missing 
ElementRule
Adverse
Events
(AE)Start 
Dateday,
month, 
and yearNoImputation for completely missing dates
day,
monthIf study treatment start date is missing (i.e. subject did 
not start study treatment), then set start date =January 1.
Else if study treatment start date is not missing:
oIfyear of start date =yearof study treatment start
date then
If stop date contains afulldate and
stop date is earlier than study  
treatment start date then set start date
= January 1.
Else set start date =study treatment
start date.
oElse set start date = January 1.
day If study treatment start date is missing (i.e. subject did 
not start study treatment), then set start date = 1st of 
month.
Else if study treatment start date is not missing:
oIf month and year of start date =month and year
of study treatment start date then
Ifstop date contains afulldate and 
stop date is earlier than study
treatment start date then set start 
date= 1st of month.
Else set start date =study treatment
start date.
oElse set start date = 1st of month.
End
DateNo imputation for partial end dates will be performed
Anti -Cancer Therapy and Radiotherapy:
Start and end dates are generally  not imputed.
Imputed partial dates will not be used to derive time since most recent prior therapy .In
addition, the cancer therapy treatment status variable, and not any variables that use
imputed partial dates, willbeused todifferentiate prior andfollow -
upanti-cancer therapy
and radiotherapy .

19CONFIDENTIA L
BRF117277
Dataset Date Missing 
ElementRule
Anti-Cancer
Therapy
RadiotherapyStart 
Dateday,
month, 
and yearNoImputation for completely missing dates
day,
monthIf partial date contains ayear only set to January
1st.
day If partial date contains a month and yearset to the
1st of the month.
End
DateNoimputation forpartial enddates willbe 
performed
Surgery:
The date of surgery or procedure is generally not imputed. However, post treatment
surgery or procedure dates maybeimputed (ifnecessary ) to determine date of new anti -
cancer therapy . In this case only , the date of new anti -cancer therapy (not specific surgery
or procedure date) will be stored on appropriate efficacy datasets. The category for
surgical procedure variable, and not an y variables thatuse imputed partial dates, will be
used to differentiate prior, on, and follow -upsurgical procedure data. The derived time in
relation to treatment variables arenotneeded forreporting ofdata because the category
for surgical procedure variable can be used. Therefore, imputed dates are not needed for
derivat ion of time in relation to treatment.
Dataset Missing 
ElementRule
Surgical
Proceduresday,month,
and yearNoImputation for completely missing dates
day,month If partial date contains ayear only set to January
1st.
day If partial date contains a month and yearset to the
1stof the month
Concomitant Medication and Blood and Blood Supportive Care Products:
Start and end dates for use in derivation of the reference variables for concomitant 
medication start and end relative to treatment will be imputed. Similarly start and end 
dates for use in derivation of the reference variables for blood and blood supportive care
start and end relative to treatment will be imputed. However these imputed start and end 
dates will not be stored permanently  in the analy sis datasets.
20CONFIDENTIA L
BRF117277
The reference variables will be used to differentiate before, during and after for the
concomitant medication orblood orblood supportive care start and end dates. The
derived time in relation to treatment variables are not needed for reporting of these data.
21CONFIDENTIA L
BRF117277
Dataset Date Missing 
ElementRule
Concomitant 
Medication
Blood and
Blood
Supportive 
Care
ProductsStart 
Dateday,
month, 
and yearNoImputation for completely missing dates
day,
monthIf study treatment start date is missing (i.e., 
subject did not start study treatment), then set
start date = January 1.
Else if study treatment start date is not missing:
oIfyear of start date =yearof study
treatment start date then
Ifstop date contains afulldate and 
stop date is earlier than study  
treatment start date then set start 
date = January 1.
Else set start date =study
treatment start date.
oElse set start date = January 1.
day If study treatment start date is missing (i.e. 
subject did not start study treatment), then set 
start date = 1st of month.
Else if study treatment start date isnotmissing:
oIf month and year of start date =month
and yearofstudy treatment start date then
Ifstop date contains afulldate and 
stop date is earlier than study  
treatment start date then set start 
date= 1st of month.
Else set start date =study
treatment start date.
oElse set start date = 1st of month.
End
Dateday,
month, 
and yearNoImputation for completely missing dates
day,
monthIf partial end date contains yearonly,set end date
=earliest of December 31 or date of last contact.
day If partial end date contains month and year,set
end date = earliest of last day of the month or date 
of last contact (MSTONE.LCONTDT).
22CONFIDENTIA L
BRF117277
Time to Event, Response, and Response for Independent Review:
Start dates for follow-up anti-cancer therapy ,radiotherapy (where applicable), and
surgical procedures (where applicable) willbetemporaril yimputed in order to define
event and censoring rules for progression -freesurvival; intracranial, extracranial, and
overall response rate; and duration of intracranial, extracranial, and overall response (i.e. ,
start date for new anti -cancer therapy ).Dateswillonly be imputed when a month and
yearare available but the day is missing. The imputed date(s) will not be stored on the
anti-cancer therapy ,radiotherapy , or surgical procedure datasets. The following rules will
be used to impute the date when partial start dates are present on anti-cancer therapy
radiotherapy ,and/or surgical procedures dataset[s]:
Dataset Date Missing 
ElementRule
Anti-Cancer
Therapy
Where
applicable:
Radiotherapy
Surgical
ProceduresStart 
Dateday,month,
and yearNoImputation for completely missing dates
day,month No imputation for missing day and month 
(note the eCRF should only allow for
missing day )
day If partial date falls in the same month as the 
last dose of study treatment, then assign to 
earlier of (date of last dose of study  
treatment+1, last day of month).
If partial date falls in the same month as the 
subject’s last assessment and the subject’s
last assessment is PD, then assign to earlier 
of (date of PD+1, last day of month).
If both rules above apply ,then assign to
latest of the 2dates
Otherwise, impute missing day to the first of 
the month.
End
DateNo imputation for partial end dates will be
performed
23CONFIDENTIA L
BRF117277
The date of new anti -cancer therapy is derived as the earliest date of new anti-cancer
therapy (e.g., chemotherapy ),radiotherap y(where applicable), or acancer -related
surgical procedure (where applicable) and will include imputed dates. Ifthe date of new
anti-cancer therapy  is an imputed date, then the date of new anti -cancer therapy flag
variable is assigned the value of 'D' to indicate that the day portion of the date is imputed 
(following ADaM convention).
As multiple dates are used to derive the date of new anti -cancer therapy ensure that the
date of new anti -cancer therapy  flag isonly set to ‘D’ if the derived date is imputed. For
example if the date of new radiotherapy  is imputed but the date of new anti -cancer
therapy isprior to date of new radiotherap yand the new anti -cancertherapy date is not a
partial date then the flagshould be set to missing as the date used for the new anti-cancer
therapy is not an imputed date.
9.2.6. Imputation ofMissing Exposure End Dates
The rules for imputing missing exposure end dates given in this section apply to both
dabrafenib and trametinib.  Thestudy treatment end date variable will hold the last date
of exposure for either dabrafenib or trametinib, that is, the latest exposure end date across
all study treatments.
In general, completely missing dates are not imputed. However, subjects in oncology
trials may still be on study treatment when analy ses are performed and so may have
missing exposure end dates in their last dosing record. Missing exposure end dates for
subjects who are still on study treatment at the time of an analy siswill be imputed. For
subjects with missing exposure end dates at the time of data cutoff, the exposure end date
willbeimputed totheearliest of:the date of the data cutoff, the date of withdrawal from
the study ,or the death date. The imputed exposure end date will be used to calculate
cumulative dose and exposure duration. The imputed exposure end date will be stored in
the ex posure analy sisdataset and an exposure end date imputation flag variable will be
derived indicating which exposure end date records are imputed. Imputed exposure end
dates will also be stored on the study treatment end date variable.
For subjects who have missing end dates in their last exposure record because they are 
still on study treatment, the on -therapy indicator variables (time in relation to study
treatment) are assigned to on- therapy  for all records where the 'dataset'.'date' is after or on
the study treatment start date.
9.2.7. Baseline Definition
Baseline will be defined as the most recent, non- missing value prior tooronthefirst
study treatment dose date. For laboratory data, baseline willbedefined asthemost recent,
non-missing value from a central laboratory prior to or on the first study treatment dose
date. If there are no central labs collected for asubject and lab test prior to or on the first
dose of study treatment, the most recent, non-missing value from a local laboratory prior
to or on the first dose of study treatment will be def ined as the baseline value.
For subjects who did not receive study treatment during the study ,baseline will be
defined asthelatest, non- missing collected value.
24CONFIDENTIA L
BRF117277
9.2.8. Change from baseline
Change from baseline will be presented for safety data as described in Section 12.
Change from baseline is calculated as:
For records occurring after baseline: (visit value) –baseline value.
Percent change from baseline is calculated as:
For records occurring after baseline: ((change from baseline) /baseline value) *100
If either the baseline or visit value is missing, the change from baseline and/or percent
change from baseline is set to missing as well.
9.2.9. Multiple Assessments
Alldata will be reported according to the nominal visit date for which it was reported
(that is, no visit windows willbeapplied during dataset creation). Unscheduled data will
only be included in the display sections that report worst -case post-baseline.
If multiple assessments on different daysare reported for the same scheduled assessment,
then the earliest assessment for that scheduled assessment will be analy zed.
If multiple assessments are reported on the same date for the same scheduled planned
time, then the worst -case result will be anal yzed, with the exception of laboratory data
reported from both central and local laboratories. If laboratory data is reported from both
central and local laboratories with the same date, then the central laboratory data will be 
analy zedto provide consistency with measurements from other subjects.
Data from all assessments (scheduled and unscheduled), including multiple assessments, 
will be included in listings.
9.2.10. ActualTreatment
The subjects’ actual treatment will be derived from exposure data. If asubject’s actual
treatment is the same as the assigned treatment, then actual treatment is the assigned
treatment. If asubject receives astudy treatment that is different from the assigned
treatment for the entire time of treatment, then actual treatment is the treatment actually
received.
9.2.11. Extended Loss to Follow -up or Extended Time without an
Adequate Assessment
Iftwo or more consecutive scheduled disease assessments are missed and are then
followed byan asses sment of PD or death, PFS will be censored at the last adequate
assessment prior to PD or death. When the scheduled disease assessment is every 8
weeks, a window of 119 days(16 weeks + 7daywindow) will be used to determine
whether there was an extended time without adequate assessment. That is, if the time
difference between the PFS event of PD or death and the last adequate assessment is
25CONFIDENTIA L
BRF117277
more than 119 days,then PFS will be censored at the last adequate assessment prior to 
the PFS event. IftheWeek 4andWeek 8disease assessments areboth missed orare
inadequate (that is, the first adequate disease assessment is at Week 16), and the Week
16 disease assessment shows progressive disease, then PFS will be set to Day 1.
9.2.12. Date Associated with Response
For each disease assessment after baseline, determine thedates associated with
intracranial, extracranial, and overall response. For anytype of complete response (CR)
or partial response (PR), assign to the latest date within the disease assessments. For any
type of stable disease (SD), Non-CR/Non -PD or Not Evaluable, assign to the earliest date
within the disease assessments. For anytypeof progressive disease (PD), assign to the
earliest assessment date associated with the progression.
9.2.13. Cardiac Scan Modalities (ECHO/MUGA )
The same modality  (ECHO or MUGA) for determining cardiac scan data (e.g., left
ventricular ejection fraction (LVEF)) should be used to follow a subject throughout the
study .The absolute change from baseline values wil l not be calculated foranysubjects
where the post -baseline value was determined b y acardiac scan modality that is different
than the one used to determine baseline value.
9.2.14. Derived and Transformed Variables
See Section 11for details on analy ses for intracranial, extracranial, and overall response,
progression -freesurvival, overall survival, duration of intracranial response, duration of
extracranial response, and duration of overall response.
Prognostic Factors
The prog nostic variables below will be added to the following datasets to support 
exploratory analy ses:  ADSL ,demography ,overall response, overall response
independent review (if there is independent review), and time to event datasets.
Baseline ECOG performance status: Baseline ECOG performance status can be 0, 1, or 2,
depending on cohort.   Assign the baseline ECOG performance status value.
Visceral Disease at baseline canbeyesor no; assign as follows:
1 =Yes
0 =No
Number of extracranial disease sites at baseline (will be adjusted based on the
distribution of the data if appropriate).   Sum thenumber ofunique sites ofdisease at
screening and assign as follows:
1 =More than 3
0 = 2 or fewer
26CONFIDENTIA L
BRF117277
Number of intracranial target lesions at baseline (will be adjusted based on the
distribution of the data if appropriate). Sum the number of intracranial target lesions at
screening and assign as follows:
4 = 5
3 = 4
2 = 3
1 = 2
0 = 1
Number of intracranial non -target lesions at baseline (will be adjusted based on the
distribution of the data if appropriate). Sum the number of intracranial non -target lesions
at screening and assign as follows:
4 = 5 or more
3 = 4
2 = 3
1 = 2
0 = 1
Gender covariate: Assign
1 =Female
0 =Male
AGE (continuous)
Age atbaseline categorized asfollows: 
1 =More than 65 yearsold
0 =No more than 65 yearsold
The time since initial diagnosis of intracranial disease to treatment category:
1 =At least 1year
0 =Less than 1year
The time since initial diagnosis of extracranial disease to treatment category:
1 =At least 1year
27CONFIDENTIA L
BRF117277
0 =Less than 1year
Race categorized as follows:
2 =Other
1 =African -American
0 = White
Censoring Date for Progression Free Survival and Duration of Intracranial, Extracranial,
and Overall Response
Date of new anti -cancer therapy  flag: Ifthe date of new anti -cancer therapy is an imputed
date, then set to ‘D’. Otherwise settomissing. SeeSection 9.2.5 for specific rules for
imputing partial dates. As multiple dates are used to derive the date of new anti-cancer
therapy ensure that the flag is only populated if the derived date is imputed. For example,
if the date of new radiotherapy is imputed but the date new anti -cancer therapy is prior to
date of new radiotherapy and the new anti -cancer therap ydate is not apartial date then
the flag should be set to missing as the date used f orthe date of new anti-cancer therapy
is not an imputed date.
9.2.15. Cut-offdate
The analy sis cut -offdate for the primary analysisofstudy data will be established. The
primary efficacy analy siswill be performed when all subjects in cohort A have had the
opportunity for three (3) post baseline disease assessments. All statistical analy seswill be
performed using all data collected inthedatabase up tothedata cutoff date. All data with
an assessment date or event start date (e.g. vital sign assessment date orstart date ofan
adverse event) prior toor on thecut-offdate willbeincluded intheanaly sis.Any data
collected beyondthecut-offdate willnot be included in the analy sisand will not be used
for anyderivations. All events with start date before or on the cut -off date and end date
after the cut -offdate will be reported as ‘ongoing’. The same rule will be applied to
events starting before or on the cut -off date and not having documented end date. Thi s
approach applies, in particular, to adverse event and concomitant medication reports.
9.3. Stud yTime Periods
9.3.1. Time in Relation to Treatment
Adverse events, serious adverse events, death, laboratory data, vitals, ECG, and
ECHO/MUGA data will be assigned to the study time periods defined below. Partial
dates will be imputed into full dates, if applicable, for slotting data to the appropriate

28CONFIDENTIA L
BRF117277
categories below (see Section 9.2.5 ).Flag variables (time in relation t o study treatment)
indicating the study time periods willbeadded tothese datasets.
Pre-therapy isdefined asthetime prior tothesubject’s firstdose ofstudy treatment.
On-therapy is defined as the time from first dose of study treatment to 30 day safter the
last dose date of study treatment.
Extension is defined as the time from overall progression + 1 day to the last dose date of
study treatment.
Post- therapy is defined as any time beyondthe on-therapy  period if study treatment
stops then, or after the extension period if study treatment is continued beyond initial 
progression.
Some datasets include the first dose day as On-therapy and some exclude the first dose
date as On -Therapy .The first dose day (Day 1) is considered pre-therapy for ECOG ,
ECG, vital signs, liver events, lab tests, and cardiac scan. The first dose day (Day 1) is
considered to be On -therapy for adverse events and concomitant medications.
9.3.2. Study Time Periods for Concomitant Medications and Blood and
Blood Supportive Care Products
Concomitant Medication and Blood and Blood Supportive Care Product start and end
dates will be assigned to study time periods in relation to first dose of study treatment as 
defined below. The start date references time flag variables and end dat e reference time
flag variables will be added to the concomitant medications and blood and blood 
supportive products datasets, respectivel y.
Start relative totreatment: Assign to 'BEFORE' if start date is prior to study
treatment start date or if subject has not taken an y study treatment or (start date is
missing and end date is before study treatment start date). Else assign to 'DURI NG'
if the start date falls into the on- therapy  period as defined above or if subject is
ongoing (not all study treatment discontinuation records completed) or start date is
missing.   Else assign to 'AFTER' if start date is after the on- therapy period.
End relative to treatment: Assign to 'BEFORE' if end date is prior to stud ytreatment
start date orifsubject hasnottaken anystudy  treatment. Else assign to 'DURI NG'if
start date falls into the on -therapy  period or if subject is ongoing (not all study
treatment discontinuation records completed) or(end date ismissing andstart
relative to treatment not 'AFTER'). Else assign to 'AFTER' if start date is after the
on-therapy  period or (end date is missing and start relative to treatment='AFTER') .
Only on-therapy blood and blood supportive care products that start after the start of
study treatment are included in the Blood Products and Blood Supportive Care Product
summaries. Therefore, for summary tables, include blood and blood supportive care
product records where start relative to treatment in ('DURING') and end relative to
treatment in ('DURING','AFTER'). All da ta will be reported in listings.
29CONFIDENTIA L
BRF117277
Concomitant medication start relative to treatment and end relative to treatment flags are
used to select data to include in the Concomitant Medication summaries as follows:
Summary of Concomitant Medication s: This summary willcontain medications 
including those with start date prior to study treatment start date and continue 
(missing end date or end date after study treatment start date) on therapy .Note that
anymedications with start date and end date prior to study treatment start date willbe
excluded as they are not concomitant. In addition, any medication that was started 
during post -therapy will be excluded. Include concomitant medication records where
start relative to treatment in('BEFORE','DURING') and end relative to treatment in
('DURI NG','AFTER').
9.4. Values ofPotential Clinical Importance
9.4.1. Laboratory Parameters
Reference ranges for all laboratory parameters collected throughout the study are 
provided bythe laboratory .A laboratory value that is outside the reference range is
considered either high abnormal (value above the upper limit of the reference range) or
low abnormal (value below the lower limit of the reference range). Note: a high abnormal
or low abnormal laboratory value is not necessarily ofclinical concern. The laboratory
reference ranges will be provided on the listings of laboratory data. Clinical laboratory
test results outside ofthereference range willbeflagged inthelistings.
To identify laboratory values of potential clinical importance, National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI -CTCAE v4.0) will be used to
assign grades to the relevant laboratory parameters. NCI-CTCAE v4.0 can be found at
http://ctep.cancer.gov/reporting/ctc.html.
For laboratory data which are not listed in the NCI CTCAE v4.0, asummary of values
outside the normal range will be provided.
9.4.2. ECG Parameters:
The foll owing criteria will be used to flag electrocardiogram (ECG) values that are values 
of potential clinical importance:
To identify QTc (Bazett’s) values of potential clinical importance, NCI-CTCAE v4.0 will
be used to assign grades (see adverse event ‘Elect rocardiogram QT corrected interval 
prolonged’). Note that there is a slight inconsistency between CTCAE v4 and ICHE14
(Absolute QTc interval prolongation). Itwas decided to align with CTCAE for the
oncology standard categories.
30CONFIDENTIA L
BRF117277
ECG Parameter Potential Clinical Importance (PCI) Range Unit
Absolute QTcB interval 450 to <481 (Grade 1)
481 to <501 (Grade 2)
501 (Grade 3)Msec
Increase from baseline
QTcBIncrease of 31 to 60
Increase of >60Msec
The following criteria will be used to flag other ECG values that are values of potential 
clinical importance:
ECG Parameter Potential Clinical Importance (PCI) Range Unit
PR interval <110 (L) and >220 (H) Msec
QRS interval <75 (L) and >110 (H) Msec
9.4.3. Vital Signs
To identify heart rate values of potential clinical importance, NCI-CTCAE v4.0 will be
used toassign categories thatalign with thegrades for‘Sinus brady cardia’, ‘Sinus
tachy cardia’, ‘Supraventricular tachy cardia’, and ‘Ventricular tachy cardia’.
The following criteria will be used to flag vital sign values that are values of potential 
clinical importance:
Vital Sign Parameter Potential Clinical Importance (PCI) Range Unit
Decrease from baseline
Heart RateDecrease to <60 bpm
Increase from baseline
Heart RateIncrease to >100 bpm
To identify blood pressure values of potential clinical importance, NCI-CTCAE v4.0 will
be used to assign categories that align with the grades for ‘Hy pertension’.
31CONFIDENTIA L
BRF117277
Vital Sign Parameter Potential Clinical Importance (PCI) Range Unit
Increase from baseline
Systolic Blood Pressure120 to <140 (Grade 1)
140 to <160 (Grade 2)
160 (Grade 3)mmHg
Increase from baseline
Diastolic Blood Pressure80 to <90 (Grade 1)
90 to <100 (Grade 2)
100 (Grade 3)mmHg
To identify temperature values of potential clinical importance, NCI-CTCAE v4.0 will be
used to assign categories that align with the grades for ‘Hypothermia’ and ‘Fever’.
Vital Sign Parameter Potential Clinical Importance (PCI) Range Unit
Increase from baseline
temperatureIncrease to 38 Degrees
C
Decrease from baseline
Diastolic Blood PressureDecrease to 35 Degrees
C
9.4.4. Left Ventricular Ejection Fraction
The following criteria will be used to flag left ventricular ejection fraction (LVEF) values 
thatarevalues ofpotential clinical importance:
To identify LVEF values of potential clinical importance, NCI-CTCAE v4.0 will be used
to assign categories that align with the grades for ‘Ejection fraction decreased’.
LVEF Parameter Potent ial Clinical Importance (PCI) Range Unit
Absolute change from
baseline LVEFNo change or an yincrease
Any decrease
o>0-<10 decrease
o10-19 decrease
o20 decrease
o10 decrease and LLN
o10 decrease and below LLN
o>10 decrease and below LLN
o20 decrease and LLN
o20 decrease and below LLN%
Relative change from
baseline LVEF20 decrease and LLN
  20 decrease and below LLN%
32CONFIDENTIA L
BRF117277
10. STUDY POPULA TION
Unless otherwise stated, all tables and listings in this section will be based on the All 
Treated Subjects population, and all summaries and data listings will use treatment labels 
as specified in Section 7.
The list of display sfor Study Population, including the population to use for each display ,
is shown in Section 14of the RAP.
10.1. Disposition ofSubjects
A summary of the number of subjects in each of the analy sispopulations described in
Section 6will be provided. Inaddition, the number of subjects enrolled will be
summarized for All Treated Subjects population.  Subjects in the All Enrolled population
who are not in the All Treated Subjects population will be listed.
A summary of subject status and reason for study withdrawal will be provided. This
display will show the number and percentage of subjects who withdrew from the study ,
including primary reasons for study withdrawal. Reasons for study withdrawal will be
presented in the order they are display ed in the eCRF.
A summary of study treatment status will be provided. This display will show the number
and percentage of subjects who have completed the study ,are ongoing, or have
discontinued study treatment and a summary of the primary reasons for discontinuati on
of study treatment. Reasons for study treatment discontinuation will be presented in the
order they are display edin the eCRF. Alisting of study treatment discontinuation will be
generated. Thelisting willinclude lastdose date, andreasons for study treatment
discontinuation.
10.2. Protocol Deviations
Allthe protocol deviations willbesummarized andlistthe important 
protocol deviations and will include inclusion/exclusion deviations as well as 
other deviations.
A separate summary and listing of inclusion/exclusion deviations will also be provided.
10.3. Demographic andBaseline Characteristics
Thedemographic characteristics (e.g., age, race, ethnicity ,sex, baseline height, and
baseline body weight) will be summarized and listed. Age, height and weight will be
summarized using the mean, standard deviation, minimum, median, and maximum. In
addition, age will also be categorized and summarized by <18, 18 -64,65-74, and>74.
The count and percentage will be computed for sex and ethnicity .
Race and ra cial combinations will be summarized and listed.
Disease history and characteristics (time since initial diagnosis in months, stage at initial 
diagnosis, date of initial diagnosis) at initial diagnosis and screening will be listed.
Separate summaries of d isease characteristics at initial diagnosis and screening will be
33CONFIDENTIA L
BRF117277
provided. Medical conditions present at screening will be listed and will be summarized
bypast and current cancer -related categories.
A summary of extracranial disease burde n at baseline will be produced.
Substance use, including smoking history and alcohol use, will be summarized and listed.
Prior anti -cancer therapy will be coded using WHODrug coding dictionary, then
summarized by cohort and listed.  A listing of prior anti -cancer therapy will show the
relationship between ATC Level 1, Ingredient, and verbatim text.  A summary of the
number of prior anti -cancer therapy  regimens will also be produced.
Prior anti -cancer radiotherap ywill be summarized an d listed. Prior cancer -related
surgeries will be summarized and listed.
10.4. Treatment Compliance
Alisting ofplanned andactual treatments willbeproduced.
A listing of drug accountability data (dispensed and returned) will be produced.
A summary of overall compliance for dabrafenib and trametinib based on the exposure 
data will be produced separately . Percentage overall compliance will be summarized
using the mean, standard deviation, minimum, median, and maximum. Inadditional,
percentage overall compliance willbecategorized andsummarized by<80%, 80%- 105%,
and >105%.
The calculation ofoverall compliance isbased ontheentire interval ofdosing for
dabrafenib and trametinib. The formula for daily dose medication is compliance (%) =
[total cumulative actual dose /(duration ofstudy treatment *prescribed dose)]*100
where duration of study treatment is last dose-firstdose +1.
Alisting of overall compliance will be produced.
In addition, summaries of study treatment exposure and dose modi fications (e.g., number
ofdose reductions, number of dose interruptions) will further characterize compliance.
These analy sesaredescribed in Section 12.1 ‘Extent of Exposure’.
10.5. Concomitant Medications
Concomitant medications will be coded using WHODrug coding dictionary, summarized,
and listed. The summary ofconcomitant medications will show the number and
percentage of subjects taking concomitant medications by Ingredient. Multi -ingredient
products will be summar ized by their separate ingredients rather than as a combination of
ingredients. Anatomical Therapeutic Chemical (ATC) classification Level 1(Bod y
System) information will be included in the dataset created but will not appear on the
listing or summary .
34CONFIDENTIA L
BRF117277
In the summary of concomitant medications, each subject is counted once within each
unique ingredient. For example, if a subject takes Amoxy cillin on two separate occasions,
the subject is counted only once under the ingredient “Amoxy cillin”.
Inthesummary of concomitant medications, the ingredients will be summarized bythe
base only,using CMBASECD and CMBASE.
Aseparate listing of prior and concomitant medications of subjects with diabetes at
baseline (as reporting on the medical history page of the eCRF) will be produced.
Blood products or blood supportive care products with onset date within the on-therapy
window will be included in the summary tables. The frequency and percentage of 
subjects using blood products and blood suppo rtive care products after the start of study  
medication will be provided. Supporting listings will also be provided.
11. EFFICA CY
All efficacy
analy seswill be based on the ATS population as defined in Section 6unless
otherwise specified. All analy seswill be presented by cohort.
Efficacy assessments are based on modified RECIST 1.1.  Primary assessments will be
based on imaging data. Investigator assessments will be considered as primary
assessments. Independent Revie wer assessments, will be supplementary .
Note: If needed, the IRC charter will have further modifications toRECI ST1.1 because
ofadditional instructions needed for the independent review. Specifically ,instructions
will be provided with respect to ascites, pleural effusion, and subjects with no lesions 
documented at baseline.

35CONFIDENTIA L
BRF117277
11.1. Primary Efficacy Analysis
Intracranial Response Rate (I RR) inCohort A
The intracranial response rate (I RR) is defined as the percentage of subjects achieving a
confirmed intracranial CR or PR from the start of treatment until disease progression or
the start of new anti -cancer therapy .This will be based on investigator -assessed best
intracranial response.
Stable intracranial disease requires meeting the SD criteria at least once after the first
dose of study treatment at a minimum interval of 8 weeks. As a window of 7 day sis
allowed for scheduling, 7weeks (or 49days)will be used for anal ysis.
Tobeassigned astatus ofintracranial PR or CR, a confirm atory disease assessment for
intracranial disease should be performed not less than 4 weeks after the criteria for
response are first met.
TheIndependent Reviewer- assessed best intracranial response will also be summarized.
Subjects with Not Evaluable (NE) or missing intracranial response will be treated as non-
responders; i.e.,they will be included in the denominator when calculating the percentage.
The exact 95% CI  for the intracranial response rate will be calculated for both the interim
and final analy sis.
All data relating to intracranial response from the investigator and, if done, the
independent reviewer will be listed, including lesion measurements, response
assessments and best response.
A plot of the maximum percent tumor reduction in intracranial target lesions from
baseline will be provided. The plot will be color- coded for best intracranial response. The
subject number will be indicated on the plot.
Intracranial response will be determined using only intracranial target, non- target, and
new lesions, using the criteria specified in the protocol.
Target
LesionsNon-Target Lesions New Lesions Intracranial
Response
CR CRorNA No CR
CR Non-CR/Non -PDorNE No PR
PR Non-PDorNAorNE No PR
SD Non-PDorNAorNE No SD
NE Non-PDorNAorNE No NE
PD Any YesorNo PD
Any PD YesorNo PD
Any Any Yes PD
CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease, NA= Not
applicable, andNE=Not Evaluable
36CONFIDENTIA L
BRF117277
11.2. Secondary Efficacy Analyses
Intracranial Response (IR) inCohorts B, C, and D
Intracranial response will be summarized for Cohorts B, C, and D as for Cohort A. 
Extracranial Response (ER) inCohorts A, B, C, and D
The extracranial response rate (ERR) is defined as the percentage of subjects achieving a
confirmed extracranial CR or PR from the start of treatment until disease progression or
the start of new anti -cancer therapy .This will be based on investigator -assessed best
extracranial response.
Stable extracranial disease requires meeting the SD criteria at least once after the first
dose of study treatment at a minimum interval of 8 weeks. To be assigned a status of 
extracranial PR or CR, a confirmatory disease assessment for extracranial disease should
beperformed notlessthan 4weeks after the criteria for response are first met.
TheIndependent Reviewer- assessed best extracranial response will also be summarized.
Subjects with Not Evaluable (NE) or missin g extracranial response will be treated as non-
responders; i.e., they will be included in the denominator when calculating the percentage.
The exact95% CI for theextracranial response rate will be calculated.
All data relating to extracranial response from the investigator and, if done, the
independent reviewer willbelisted, including lesion measurements, response 
assessments and best response.
A plot of the maximum percent tumor reduction in extracranial target lesions from
baseline willbeprovided. Theplotwill be color- coded for best extracranial response.
The subject number will be indicated on the plot.
Extracranial response will be determined using only extracranial target, non-target, and
new lesions, using the criteria specified in the protocol.
Target
LesionsNon-Target Lesions New LesionsExtracranial
Response
CR CRorNA No CR
CR Non-CR/Non -PD orNE No PR
PR Non-PDorNAorNE No PR
SD Non-PDorNAorNE No SD
NE Non-PDorNAorNE No NE
PD Any YesorNo PD
Any PD YesorNo PD
Any Any Yes PD
CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease, NA= Not
applicable, andNE=Not Evaluable
37CONFIDENTIA L
BRF117277
Overall Response (OR) in Cohorts A, B, C, and D
The overall response rate (ORR) isdefined asthepercentage ofsubjects achieving a
confirmed overall CR or PR from the start of treatment until disease progression or the
start ofnew anti-cancer therapy . This will be based on investigator -assessed best over all
response.
Stable disease requires meeting the SD criteria forboth intracranial andextracranial
disease at least once after the first dose of study treatment at aminimum interval of 8
weeks.   To be assigned a status of overall PR or CR, a confirmato rydisease assessment
for both intracranial and extracranial disease should beperformed notlessthan 4weeks
after the criteria for response are first met.
TheIndependent Reviewer- assessed best overall response will also be summarized.
Subjects with Not Evaluable (NE) or missing overall response will be treated as non-
responders; i.e., they will be included in the denominator when calculating the percentage.
The exact95% CI for theoverall response rate will be calculated.
All data relating to overall response from the investigator and, if done, the independent
reviewer will be listed, including lesion measurements, response assessments and best
response.
A plot of the maximum percent tumor reduction in overall target lesions from ba seline
will be provided. The plot will be color- coded for best overall response. The subject
number will be indicated on the plot.
Overall response will be determined using both extracranial and intracranial target, non-
target, and new lesions, using the criteria specified in the protocol. Overall target lesion
response isbased onall(that is, intracranial and extracranial) target lesions, up to 10 total.
The sum of longest diameters of all intracranial and extracranial target lesions will be
used todetermine overall response. Unequivocal new intracranial or extracranial (or 
both) lesions, or unequivocal intracranial or extracranial (or both) non- target lesion
progression indicate overall progression. Target, non-target, and new lesion responses
are co mbined as for intracranial and extracranial response to determine response at each 
disease assessment and best overall response.
Complete Response (CR): Disappearance of all intracranial and extracranial target
lesions. Any pathological lymph nodes must be <10mm in the short axis.
Partial Response (PR): At least a 30% decrease in the sum ofthediameters of
intracranial and extracranial target lesions, taking asareference, the baseline sum of 
the intracranial and extracranial diameters (e.g. percent change from baseline).
Stable Disease (SD): Neither sufficient shrinkage to qualify forPR nor sufficient
increase to qualify for progressive disease.
Progressive Disease (PD): At least a20% increase in the sum of the diameters of
intracranial and extracranial target lesions, taking as a reference, the smallest sum of 
intracranial and extracranial diameters recorded since the treatment started (e.g.,
38CONFIDENTIA L
BRF117277
percent change from nadir, where nadir is defined as the smallest sum of diameters 
recorded since treatment start). In addition, the sum must have an absolute increase 
from nadir of 5mm.
Not Evaluable (NE): Cannot be classified b yone of the five preceding definitions.
Intracranial, Extracranial, and Overall Disease Control in Cohorts A, B, C, and D
The intracranial disease control (IDC), extracranial disease control (EDC), andoverall 
disease control (ODC) are defined as CR+PR+SD for intracranial, extracranial, and
overall disease control, respectively .Disease control rates aredefined asthepercentage
of subjects achieving a confirmed overall CR or PR, or SD for at least 8 weeks from the
start of study treatment, from the start of treatment until disease progression or the start of 
new anti -cancer therapy .This will be based on investigator -assessed responses.
TheIndependent Reviewer- assessed disease control rate willalsobesummarized.
Subjects with Not Evaluable (NE) or missing intracranial, extracranial, or overall
response will be treated as non- responders; i.e., they will be included in the denominator
when calculating the percentage.
Exact 95% CI sfor the disease control rates will be calculated.
Duration of Intracranial, Extracranial, and Overall Response in Cohorts A, B, C, and D
Duration of intracranial, extracranial, and overall response will be summarized separately
for subjects with a confirmed of intracranial, extracran ial,or overall CR or PR and is
defined as the time (in months) from the initial response (CR/PR) to first documented 
disease progression or death due to anycause. This will be based on responses from the
investigator assessment. Censoring rules will follow those of the primary PFS analy sis
defined in Section 11.1.
If sample size permits, the median duration of response will be calculated from the 
Kaplan -Meier estimates. First andthird quartiles willalsobecalculated along with
associated 95% confidence intervals if there are a sufficient number of responders who 
subsequently progress or die due to any cause.
Figures andlistings ofduration ofresponse willalsobeprovided.
The duration ofintracranial, extracranial, and overall response per independent reviewer -
assessment willalsobesummarized. Figures andlistings ofduration ofindependent
reviewer- assessed response will also be provided.
Progression -Free Survival in Cohorts A, B, C, and D
Progre ssion -Free survival (PFS) is defined as the interval of time (in months) between the
date of first dose of study treatment and the earliest of the date of overall disease
progression and the date of death due to anycause. Disease progression will be based on
assessments bythe investigator.
39CONFIDENTIA L
BRF117277
Thedate ofdocumented disease progression willbedefined asthedate ofoverall disease
progression based on imaging data. The date of death will be taken from the Record of
Death page. Death on study duetoanycause will beused.
Subjects who progressed or died after an extended period without adequate intracranial
and extracranial assessment will be censored at their date of last adequate intracranial and
extracranial assessment prior to progression or death even if subsequent information is
available regarding intracranial or extracranial progression or death. An adequate
assessment isdefined as
anassessment where theinvestigator -determined response isCR,
PR, or S D. The date of response at that assessment will be used for censoring. Because
the assessment schedule changes during study treatment, specific rules for identify ing
extended loss to follow -up or extended time without an adequate assessment are provided
inSection 9.
If anti -cancer therapy is started without documented overall disease progression or is
started prior to documented overall disease progression, then PFS will be censored at the
date of the last adequate assessment that is on or before the date of 
initiation of anti -
cancer therapy (i.e., if an assessment occurs on the same day as the start of new anti -
cancer therapy  the assessment will be used). The date of response at the last adequate
assessment will be used as the censoring value.
If a subject has only a baseline visit or does not have an adequate assessment that is on or
before the date of initiation of anti -cancer therapy , PFS will be censored at the date of
first dose of study treatment.
Ifasubject hasneither progressed nordied norstarted new anti-cancer therapy ,then PFS
will be censored at the date of the last adequate assessment defined as an assessment 
where theinvestigator -assessed response  is CR, PR, SD. The date of response will be
used as the censoring date.
A summary of the assignments for progression and censoring dates for PFS are specified 
in Table 2.
Table 2 Assignments for Progression and Censoring Dates for PFS Analysis
Situation Date of Event
(Progression/Death) or
CensoringOutcome
Event (Progression/Death) 
Or Censored
No(or inadequate) baseline
intracranial and extracranial 
tumor assessments and the
subject has not diedFirst dose of study
treatmentCensored

40CONFIDENTIA L
BRF117277
Situation Date of Event
(Progression/Death) or
CensoringOutcome
Event (Progression/Death) 
Or Censored
Nopost-baseline
intracranial or extracranial
assessments and the subject
hasnotdiedFirst dose of study
treatmentCensored
Progression documented
between scheduled visitsDate of assessment of
earliest source of
progression1Event
No progression (or death) Date of last adequate
assessment ofresponse2Censored
New anticancer treatment
started prior to documented
disease progression3Date of last adequate
assessment ofresponse2on
or before starting new anti -
cancer therapyCensored
Death before first PD
assessment (including
death at baseline or prior to 
anyadequate assessments)Date of death Event
Death between adequate
assessment visitsDate of death Event
Death or progression after 
more than one missed visitDate of last adequate
assessment ofresponse2
prior to missed assessmentsCensored
1The earliest of (i) date of radiological assessment showing new intracranial or
extracranial lesion (if progression is based on a new lesion); or (ii) date of radiological
assessment showing unequivocal progression inintracranial or extracranial non target
lesions, or (iii) date of last radiological assessment of measured intracranial and
extrac ranial lesions (if progression is based on increase in sum of measured intracranial
and extracranial lesions)
2An adequate assessment is defined as an assessment where the Investigator determined
response is CR, PR, or SD.
3If PD and new anti-cancer therapyoccur on the same day assume the progression was
documented first; e.g., outcome is progression and the date is the date of the assessment
of progression). Ifanti-cancer therapy is started prior to any  adequate assessments,
censoring date should be the date of firstdose of study treatment.
41CONFIDENTIA L
BRF117277
PFS will be summarized using Kaplan -Meier estimates. Frequency of patients with PFS
events willbepresented andalsoseparatel ybytypes of PFS event, i.e. progression or
death. Ifthere areasufficient number ofprogressions ordeaths, median PFS, firstand
third quartiles, and 95% CIswill be estimated using the Brookmey er-Crowley method
[Brookmey er,1982]. A figure and listing of progression -freesurvival time will also be
provided.
PFS per independent reviewer -assessment will be summarized. A figure and listing of
progression -freesurvival time per independent reviewer will also be provided.
Overall Survival in Cohorts A, B, C, and D
Overall Survival (OS) isdefined astheinterval oftime (inmonths) between thedate of 
first dose of study treatment and the date of death due to any cause. For subjects who do 
not die, time of death will be censored at the date of last contact. The date of death should
be taken from that recorded on the Record of Death page. Death on study duetoany 
cause will be included.
The date of last contact will be assigned to the latest date of: Exposure, randomization, 
death date, follow -up contact, or anyactual assessment/procedure date in any data set.
The following dates will NOT be included in the date of last contact calculations:
Date of birth, date of initial cancer diagnosis, date when metastatic disease was 
first diagnosed, and date of disease staging at screening: These dates are prior to
randomization.
Date of withdrawal from the study :This date may not be associated with an
actual subject visit.
Date of protocol deviation: This date may not be associated wit h an actual 
assessment.
Date of when dispensed investigational product bottles were returned: This date 
may not be associated with an actual subject visit. For example, a relative could
return un -used drugs.
Date when asample wasanaly zedfor BRAF mutation: This date is not
associated with an actual subject visit.
If there are no post baseline data then the date of randomization will be the last contact 
date.
Survival will be summarized using the Kaplan -Meier for each cohort. In additio n to the
Kaplan -Meier estimates for median overall survival time, the first and third quartiles will
be presented, along with approximate 95% CIs if there are a sufficient number of deaths.
Agraph ofsurvival curves andalisting ofsurvival times willalsobeprovided.
Analy seswill be conducted at the time of the primary endpoint analy sisas well as at the
end of the study .
42CONFIDENTIA L
BRF117277
11.3. Other Efficacy Analyses
Summaries of comparisons between I nvestigator assessment and Independent Reviewer
assessment oftheBest intracranial, extracranial and overall Response for each subject
will be provided overall by cohort. Also, a summary of comparison between investigator
assessment and independent reviewer assessment of progression free survival times will
be provided.
Concordance Analy sisofIntracranial, Extracranial, and Overall Response Rates
An assessment of the concordance between Independent Reviewer assessment and
Investigator Assessment of the Best Intracranial, Extracranial, and Overall Response for
each subject will be provided overall across all cohorts. The calculation will be based on
the percent agreement (the proportion of response outcomes that agree or match across 
both Independent Reviewer and Investigator Assessments):
Percent Agreement = (Number of matched responders + Number of matched non-
responders) /total number of subjects assessed.
12. SAFETY ANAL YSES
Unless otherwise specified, all the safety analy seswill be based on the All Treated
population as defined in Section 6and summaries will include all events and assessments
collected during the study. All the analy ses will be performed bycohort.
The list of display sfor safety analyses are shown in Section 14of the RAP.
12.1. Extent ofExposure
Extent of exposure to dabrafenib and trametinib will be summarized separatel y.
The duration of exposure to study treatment in months (from first day to last day of
treatment) will be summarized. Descriptive statistics including mean, median, standard
deviation, minimum, and maximum will be calculated for time on study treatment.
Moreover, time on study treatment will be categorized in different time period: <3
months, 3 months to 6 months, >6 months to 12 months and >12 months.
The subject’s average daily dose, defined as the cumulative dose divided by  the duration
of exposure for each subject, will be summarized.
Dose reductions will be summarized by number of reductions and reasons for reductions 
for dabrafenib and t rametinib separately .Dose interruptions will be summarized by
number of interruptions, reasons for the interruptions, and interruption duration (days) for
dabrafenib and trametinib separately .The mean, standard deviation, median, minimum
value, and maximum value will be computed for the duration of interruptions as well as
thenumber andpercentage oftheinterruptions ≤7,8-14, 15 -21and >21 days.
All the dose reductions and dose interruptions will be listed separatel y.
43CONFIDENTIA L
BRF117277
12.2. Adverse Events
Adverse events (AEs) will be graded according to the CTCAE, Version 4.0. Adverse 
events will be coded to the preferred term (PT) level using the Medical Dictionary for
Regulatory Affairs (MedDRA dictionary ).
AEsummaries willusethefollowing algorithms forcounting subjects:
Preferred term row :Subjects experiencing the same AE preferred term several
times with different grades will only be counted once with the maximum grade.
Any event row : Each subject with at least one adverse event will be counted only
once at the maximum grade no matter how many events they have.
An overview summary of AEs, including counts and percentages of subjects with any AE,
AEs related to study treatment, AEs lead ing to permanent discontinuation of study
treatment, AE leading to dose reductions, AEs leading to dose interruptions, SAEs, SAEs 
related to study treatment, fatal SAEs, andfatal SAEs related tostudy treatment will be
produced. The same overview summary will be produced by sex and age groups (<65
and 65yearsold)
The frequency and percentage of AEs (all grades) will be summarized and display ed in
twoways:1) in descending order of total incidence by PT only and 2) in descending
order of total incidence by Sy stem Organ Classes (SOC) and PT. In the SOC row, the
number of subjects with multiple events under the same system organ class will be
counted once.
A summary of common (that is, that occurred in strictly 5% of the subjects or above)
non-serious AEs will be provided. No rounding for the percentage will be used in terms
of 5% threshold, e.g., event with 4.9% incidence rateshould not be included in this table.
The summary will be display edbySOC and PT.
A summary of number and percentage of subjects with any adverse events by maximum 
grade will be produced. AEs will be sorted byPreferred term (PT) in descending order of
total incidence.
Therelationship between MedDRA SOC, PT,andVerbatim Text will be listed.
Aseparate summary for dabr afenib related, trametinib related, and dabrafenib and
trametinib related AEs will be provided for study treatment -related AEs. Astudy
treatment -related AE is defined as an AE for which the investigator classifies the
relationship to study treatment as “Yes”. Aworst case scenario approach willbetaken to
handle missing relatedness data, i.e. the summary table will include events with the
relationship to study treatment as ‘Yes’ or missing. The summary table will be display ed
in descending order of tota l incidence byPTonly for each drug.
All AEs will be listed. Additionally , a listing of subject IDs for each individual AE will
be produced.
44CONFIDENTIA L
BRF117277
12.3. Adverse Events ofSpecial Interest
Acomprehensive list of MedDRA terms based on clinical review will be used to identify
each typeof events. Changes to the MedDRA dictionary  may  occur between the start of
the study and the time of reporting and/or emerging data from on- going studies may
highlight additional adverse events of special interest, therefore the list of terms to be 
used for each event of interest and the specific events of interest will be based on the 
safet yreview team (SRT) agreements in place at the time of reporting.
An overview summary of AEs of special interest, including counts and percentages of 
subjects with any AE, AEs related to study treatment, AEs leading to permanent 
discontinuation of study treatment, AE leading to dose reductions, AEs leading to dose
interrupt ions, SAEs, SAEs related to study treatment, fatal SAEs, and fatal SAEs related
tostudy treatment will be produced.
The events of special interest include
Skin related toxicities
Ocular events
Cardiac related events
Hepatic disorders
Pneumonitis/Interst itiallung disease
Bleeding events
Diarrhea
Hypertension
Edema
Hypersensitivity
Pyrexia
Cutaneous squamous cellcarcinoma including Keratoacanthoma
Non-Cutaneous Treatment -Emergent Malignancies
New primary melanoma
Pre-renal and Intrinsic Renal Failure
Uveitis
Hyperglycemia
Deep vein thrombosis/pulmonary embolism
Pancreatitis
Neutropenia
45CONFIDENTIA L
BRF117277
Summaries of the characteristics of each AE of special interest, including the number and
percentage of subjects with these events will be provided for each separately. All
summaries ofAEs ofspecial interest willusethenumber ofsubjects with theevent asthe 
denominator when calculating percentages. The summary of event characteristics will 
also be provided, including number of subjects with any event, number of events, number
of subjects with anyevent that is serious, number of subjects with anyevent that is
related to study treatment, the outcome of the event, maximum grade and the action taken
for the event. The pe rcentage will be calculated using thenumber of subjects with the
event as the denominator.  The worst case approach willbeapplied atsubject level for
the event outcome and maximum grade, i.e., a subject will only be counted once asthe
worst case from alltheevents experienced bythesubject. For action taken in response to
anevent, subjects will be counted once under each action, e.g., if a subject has anevent
leading to both study treatment discontinuation anddose reduction, thesubject willbe
counted once under both actions.
Summaries of onset forcutaneous squamous cellcarcinoma including keratoacanthoma, 
and new primary melanomas (that is, AEs of special interest for which duration is not
meaningful) will be produced.  All other AEs of special interest will have summaries of
the onset and duration produced.
In addition, subjects with each AE of special interest will be listed separately byAE of
special interest.
12.4. Deaths andSerious AdverseEvents
Note thatifanysubject withdraws consent, no data after the date of withdrawing consent,
including death, is supposed to appear in the database.
All deaths will be summarized based on the number and percentage of subjects. This
summary will classify subjects by time of death relative to the last dose of medication 
(>30 day s or  30 days).Asupportive listing willbegenerated toprovide subject -specific
details on subjects who died.
All SAEs will be tabulated based on the number and percent age of subjects who 
experienced the event. Separate summaries will also be provided for dabrafenib -and
trametinib -related SAEs, fatal SAEs and dabrafenib -and trametinib -related fatal SAEs.
The summary tables will be display edin descending order of total incidence by PT only.
Adabrafenib - ortrametinib -related SAE is defined as an SAE for which the investigator
classifies the relationship dabrafenib or trametinib as “Yes”. Aworst case scenario
approach will be taken tohandle missing data, i.e. the summary table will include events
with the relationship to study treatment as ‘Yes’ or missing.
SAEs areincluded inthelisting ofalladverse events. Separate supportive listings with
subject -level details will be generated for
Fatal SAEs
Non-Fatal SAEs.
46CONFIDENTIA L
BRF117277
12.5. Adverse Events Leading toDiscontinuation ofStud y
Treatment andDose Modifications
The following categories ofAEs willbesummarized separately in descending order of
total incidence byPT only and separate supportive listings will be generated with subject
level details for those subjects:
AEs Leading to Discontinuation of Study Treatment
AEs L eading to Dose Interruptions
AEs Leadings to Dose Reductions
12.6. Pregnancies
While pregnancy itself is not considered to be an AE or SAE, any pregnancy  
complication or elective termination of a pregnancy formedical reasons willberecorded 
as an AE or SAE asdescribed intheprotocol. Ifsubjects orsubjects’ partner become
pregnant while on the study ,the information will be included in the narratives and no
separate table or listing will be produced.
12.7. Clinical Laboratory Evaluations
The assessment of laboratory toxicities will examine the following laboratory tests:
Hematology :White Blood Cell (WBC) count (absolute), Absolute Neutrophil Count
(ANC), Hemoglobin (HGB), Hemoglobin A1C, Hematocrit (HCT), Platelet count,
Basophils, Eosinphils, Lymphocy tes, Moncy tes,and Neutrophils. Basophils, Eosinphils,
Lymphocy tes,Moncy tes,and Neutrophils are expressed as percentages. Note that
hematocrit is not gradable by CTCAE v4.0.
Clinical Chemistry :Albumin, Gamma -Glutamy lTranspeptidase (GGT), Urea/Blood
Urea Nitrogen (BUN), Calcium, Creatinine, Glucose, Lactate Dehy drogenase (LDH),
Magnesium, Phosphate, Potassium, and Sodium. BUN and LDH are not gradable by
CTCAE v4.0. For Sodium, Potassium, Calcium, and Glucose there will be two bi-
directional parameters (hyper and hypo) created, and the tests will be graded by CTCAE
v4.0 in both directions.
Liver Function Tests :Aspartateamino transferase (AST), Alanine aminotransferase
(ALT), Alkaline phosphatase, and Total bilirubin (total). All these tests are gradable by
CTCAE v4.0.
Coagulation Tests :Prothrombin time (PT) or International Normalized Ratio (INR), and
activated partial thromboplastin time (APTT). INR and PTT are gradable by CTCAE
v4.0 and PT is not.  Coagulation tests are only done atbaseline.
Laboratory grades will be reported using the Common Terminology Criteria forAdverse
Events (CTCAE v4.0).
47CONFIDENTIA L
BRF117277
Summary of lab byscheduled visits using mean, median, standard deviation, minimum
andmaximum willbeprovided.
Summaries of worst case grade increase from baseline grade will be provided for all the
lab tests that are gradable by CTCAE v4.0. These summaries will display the number and 
percentage of subjects with post-baseline grade increases from their baseline grade. Any
increase in grade from baseline will be summarized along with anyincrease to a
maximum grade of 3 and any increase to a maximum grade of 4.Missing baseline grade
will be assumed as grade 0. Inaddition, the summary will include grade increase from
baseline byscheduled visits and worst -case post-baseline. For laboratory tests that are
graded for both low and high values, summaries will be done separatel yand labeled by
direction, e.g., sodium will be summarized as hyponatremia andhypernatremia.
For lab tests that are not gradable byCTCAE v4.0, summaries of worst case changes
from baseline with respect tonormal range willbegenerated. Decreases to low, changes
tonormal or no changes from baseline, andincreases tohigh will be summarized at each 
scheduled visit as well as for the worst case post -baseline. If asubject has adecrease to
low and an increase to high during the same time interval, then the subject is counted in 
both the “Decrease to Low” categories and the “Increase to High” categories. Inaddition,
the summary will include worst case changes from baseline with respect tonormal range
byscheduled visits.
Separate summary tables for hematology ,chemistry, and liver function laboratory tests
will be produced. Coagulation test results at baseline will be summarized.
Alisting of selected laboratory tests and grades will be provided.  A supporting listing of
laboratory data for subjects with values outside the normal range will be provided. A
separate listing of laboratory data with character values will also be provi ded.
Detailed derivation of baseline assessment is specified in Section 9.2.7 .
Unless otherwise specified, the denominator in percentage calculation at each scheduled
visit will be based on the number of subjects with non-missing value at each particular
visit.
Coagulation tests only collected at baseline. Therefore these tests will not appear in an y
summaries of changes from baseline.
12.7.1. Analysesof Liver Function Tests
Summaries of hepatobiliary laboratory abnormalities including possible Hy’slaw cases
willbeprovided inaddition towhat hasbeen described above.
Possible Hy ’slaw cases are defined as anyelevated ALT>3×ULN, total
bilirubin ≥2×ULN and ALP<3×ULN/missing. Total bilirubin ≥2×ULN can be within 28
days following the ALT elevation and if direct bilirubin is available on the same day,it
must be ≥ 35% of total bilirubin. ALP<3xULN/missing means the criteria is satisfied
unless the ALP is ≥3xULN at any time of bilirubin elevation within the 28 day s window.
48CONFIDENTIA L
BRF117277
LFT patient profiles plots for subjects experiencing an ALT, AST or total bilirubin of 
toxicity grade 2 or above will be produced.
A plot of maximum total bilirubin versus maximum AL Twill be generated.
12.8. Other Safety Measures
Unless other wise specified, the denominator in percentage calculation at each scheduled
visit will be based on the number of subjects with non-missing value at each particular
visit.
Vital Signs
Values of vital signs as well as the change from baseline will be summarized by
scheduled visit using mean, median, standard deviation, minimum and maximum.
In addition vital signs values will be categorized as follows:
Systolic BP (mmHg): Grade 0(<120), Grade 1 (≥120 -<140), Grade 2 (≥140 -<160)
and Grade 3 (≥160)
Diastolic BP (mmHg): Grade 0 (<80), Grade 1 (≥80-<90), Grade 2 (≥90-<100), and
Grade 3 (≥100)
Heart rate (beats/min): <60, 60-100, and >100
Temperature (°C): <35, 35<= and < 38,≥38
Summaries of increase in vital signs from the baseline with respect to the categories 
defined above will be performed. These summaries will display the number and
percentage of subjects with any grade increase, increase to grade 2 and increase to grade
3 at each scheduled assessment time and in the worst case post -baseline.
Asupportive listing will also be provided.
Performance Status
ECOG performance status will be summarized at baseline and each post-baseline
scheduled visit. Summaries will use freque ncyand percentage of subjects at each planned
assessment time. A summary of change from baseline by scheduled visits will be
performed, as well as the worst case post -baseline and the best case post -baseline changes
during the study .
Asupporting listing willalsobeprovided.
ECG
The summaries for the QTc will use the collected value only.
A summary of the number and percentage of subjects who had normal and abnormal 
(clinically significant and not clinically significant) ECG findings will be display ed by
scheduled visits as well as for the worst case post -baseline.
49CONFIDENTIA L
BRF117277
The QTc values based on Bazett’s formula will be rounded to the integer and the values
will be categorized into the following ranges: Grade 0 (<450), Grade 1 (450-480), Grade
2 (481-500), and Grade 3 (≥501).   A summary of grade shifts from baseline value for
each scheduled assessment time and in the worst case post-baseline will be provided.
Summaries of grade increase will be provided. These summaries will display the number
and percentage ofsubjects with any grade increase and increase to grade 3 at each
scheduled assessment time andintheworst case post-baseline.
Thechanges inQTc values willbecategorized intotheclinical concern ranges which are
specific to changes in QTc: 31-60and >60 msec. A summary of change in QTc value will
display thenumber andpercentage ofsubjects with achange within each range at each
scheduled assessment time andintheworst case post-baseline. Subjects with missing
baseline values will be excluded from this summary.
Listings of abnormal ECG findings and a listing of ECG values will be provided. In
addition, a listing the QTc data for subjects in each cohort an absolute QTcB interval
501 (Grade 3) and an increase from baseline QTcB of >60 at an ytime in the on -therapy
period (that is, these values do not have to be at the same assessment but the subject must 
be on study treatment or within 30 daysof the last dose of study treatment) will be
produced.
A figure plotting the baseline QTc and the worst -case post -baseline values will be
produced. The figure will have reference lines at 450 and 500 msec for both the ordinate
and the abscissa axes. There will be diagonal reference lines at equality (i.e., a45 degree
line), at equality plus 30msec, and at equality plus 60 msec.
LVEF
Absolute change from baseline in LVEF will be summarized at each scheduled
assessment time and in the worst case post -baseline. Only the post-baseline assessments
that used the same method (ECHO or MUGA) as the baseline assessments will be used to
derive the change from baseline. The change from baseline will be categorized as
follows:
Any increase
No change
Any decrease:
o0 -<10% Decrease
o10 -<20% Decrease
o≥20% D ecrease
≥10% decrease and ≥LLN
≥10% decrease and <LLN
>10% decrease and < LLN
50CONFIDENTIA L
BRF117277
≥20% decrease and ≥LLN
≥20% decrease and < LLN
LVEF results willalsobelisted with subject level details including absolute change from 
baseline.
Liver Events
Forany liver events that occur during the study ,the liver event information for RUCUM
score will be summarized, including whether the subject was age 55 or over, whether the 
subject became pregnant, liver imaging normal or not, a biopsy wastaken ornot,whether 
there was fasting or significant dietary change, whether the subject took any
unconventional medications, timing when theevent occurs (while ontreatment orafter 
stopping treatment) and summary statistics for time from first dose to star t of liver event 
and time from last dose to start of liver event. If the number of events does not support a 
summary , then only listings will be produced.
For subjects with multiple events, the first event will be used for the summary tables. All 
events w ith subject level details will be display ed inasupporting listing.
Ocular Exams
Baseline and Week 4data will be summarized based on the number and percentage of
subjects who receive an ocular exam. Because post-baseline exams are only performed as
clinically indicated, data beyondWeek 4 will only  be listed.

51CONFIDENTIA L
BRF117277
13. REFERENCES
Brookmey erR, Crowley J. A confidence interval for the median survival time.
Biometrics, 1982; 38:29 -41.
Fleiss, J.L.Statistical Methods for Rates and Proportions (1981), pp. 13 -15.
GlaxoSimthKline Document Number 2013N168168437_01, protocol, A Phase II, Open -
Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF
Mutation- Positive Melanoma that has Metastasized to the Brain. Effective Date: 27-
APR -2014
GUI_137354: Information for Authors: Reporting and Anal ysis Plans
Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. New York: John 
Wiley & Sons; 
1999.
European Medicines Evaluation Agency (CPMP/ICH/3633/96). ICHTopic E9: Statistical
principles for clinical trials. Committee for Proprietary Medicinal Products (CPMP), 
European Agency for the Evaluation of Medicinal Products. London: European
Medicines Evaluation Agency , September 1998
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika, 
1983; 70(3):659 -663

52CONFIDENTIA L
BRF117277
14. ATTACHMENTS
14.1. Table ofContents forData Display Specifications
Table Study
Pop1.0010 Summary of Study Populations by Cohort
Table Study
Pop1.1010 Summary of Number of Subjects by Centre
Table Study
Pop1.1110 Summary of Subject Disposition by Cohort
Table Study
Pop1.1220 Summary of Study Treatment Status for Trametinib by Cohort
Table Study
Pop1.1221 Summary of Study Treatment Status for Dabrafenib by Cohort
Table Study
Pop1.1310 Summary of Inclusion/Exclusion Criteria Deviations
Table Study
Pop1.1410 Summary of Protocol Deviations
Table Study
Pop1.2010 Summary of Demographic Characteristics by Cohort
Table Study
Pop1.2110 Summary of Extracranial Disease Burden at Baseline by Cohort
Table Study
Pop1.2020 Summary of Race and Racial Combinations
Table Study
Pop1.2120 Summary of Tobacco and Alcohol Use by Cohort
Table Study
Pop1.3110 Summary of Past Medical Conditions by Cohort
Table Study
Pop1.3111 Summary of Current Cancer -Related Medical Conditions byCohort
Table Study
Pop1.3210 Summary of Disease Characteristics at Initial Diagnosis by Cohort
Table Study
Pop1.3220 Summary of Disease Characteristics at Screening by Cohort
Table Study
Pop1.3230 Summary of Metastatic Disease at Screening by Cohort
Table Study
Pop1.4010 Summary of Coded Anti-Cancer Therapy by Cohort
Table Study
Pop1.4020 Summary of Prior Dictionary Coded Anti-Cancer Therapy by
Cohort
Table Study
Pop1.4030 Summary of Number of Prior Anti-Cancer Therapy Regimens by
Cohort
Table Study
Pop1.4110 Summary of Prior Cancer -Related Surgical Procedures by cohort

53CONFIDENTIA L
BRF117277
confirmation) (modified RECIST 1.1 Criteria) by Cohort
Independent Reviewer -Assessed Best Extracranial Response
(with confirmation) (modified RECIST 1.1 Criteria) by Cohort 
Independent Reviewer -Assessed Best Overall Response (with
confirmation) (modified RECIST 1.1Criteria) byCohort
Summary of Comparison of Investigator -Assessed and
Independent Reviewer -Assessed Best Intracranial Response (with
confirmation) (Modified RECIST 1.1 Criteria)
Summary of Comparison of Investigator -Assessed and
Independent Reviewer -Assessed Best Extracranial Response
(with confirmation) (Modified RECIST 1.1 Criteria)
Summary of Comparison of Investigator -Assessed and
Independent Reviewer -Assessed Best Overal Resp onse (with
confirmation) (Modified RECIST 1.1 Criteria)
Comparison of Investigator and BICR Progression -Free Survival 
Timings b y Cohort
Kaplan -Meier Estimates of Investigator -Assessed Duration of
Intracranial Response by Cohort
Kaplan -Meier Estimates of Investigator -Assessed Duration of
Extracranial Response by Cohort
Kaplan -Meier Estimates of Investigator -Assessed Duration of
Overall Response by Cohort
Kaplan -Meier Estimates of Independent Reviewer -Assessed
Duration of Intracranial Response by CohortTable Study
Pop1.4220 Summary of Duration of Follow -upby Cohort
Table Study
Pop1.5010 Summary of Concomitant Medications by Cohort
Table Study
Pop1.6010 Summary of Overall Compliance (Dabrafenib) by Cohort
Table Study
Pop1.6011 Summary of Overall Compliance (Trametinib) by Cohort
Table Efficacy 2.0020
Table Efficacy 2.0022
Table Efficacy 2.0060
Table Efficacy 2.1010
Table Efficacy 2.1012
Table Efficacy 2.1013
Table Efficacy 2.1014
Table Efficacy 2.1015
Table Efficacy 2.1016
Table Efficacy 2.1050
Table Efficacy 2.1051
Table Efficacy 2.1052
Table Efficacy 2.2010
Table Efficacy 2.6010
Table Efficacy 2.6011
Table Efficacy 2.6012
Table Efficacy 2.6013

54CONFIDENTIA L
BRF117277
Table Efficacy 2.6014 Kaplan -Meier Estimates of Independent Reviewer -Assessed
Duration of Extracranial Response by Cohort
Table Efficacy 2.6015 Kaplan -Meier Estimates of Independent Reviewer -Assessed
Duration of Overall Response by Cohort
Table Efficacy 2.7010 Summary of Concordance Between Investigator -Assessed and
Independent Reviewer -Assessed Best Intracranial Response (with
confirmation) (Modified RECIST 1.1 Criteria)
Table Efficacy 2.7020 Summary of Concordance Between Investigator -Assessed and
Independent Reviewer -Assessed Best Extracranial Response
(with confirmation) (Modified RECIST 1.1 Criteria)
Table Efficacy 2.7030 Summary of Concordance Between Investigator -Assessed and
Independent Reviewer -Assessed Best Overal Response (with
confirmation) (Modified RECIST 1.1 Criteria)
Table Safety 3.0010 Summary of Exposure to Dabrafenib by Cohort
Table Safety 3.0011 Summary of Exposure to Trametinib by Cohort
Table Safety 3.0040 Summary of Dose Reductions by Cohort (Dabrafenib)
Table Safety 3.0041 Summary of Dose Reductions by Cohort (Trametinib)
Table Safety 3.0050 Summary of Dose Interruptions by Cohort (Dabrafenib)
Table Safety 3.0051 Summary of Dose Interruptions by Cohort (Trametinib)
Table Safety 3.1010 Adverse Event Overview by Cohort
Table Safety 3.1020 Summary of All Adverse Events by Cohort (by System Organ
Class)
Table Safety 3.1030 Summary of All Adverse Events by Cohort (by Preferred Term)
Table Safety 3.1040 Summary of Common Non-Serious Adverse Events by Cohort
Table Safety 3.1070 Summary of Adverse Events By Maximum Grade and Cohort
Table Safety 3.1090 Summary of Adverse Events of Special Interest by Maximum
Grade and Cohort
Table Safety 3.1110 Summary of Adverse Events Related to Dabrafenib by Cohort
Table Safety 3.1111 Summary of Adverse Events Related to Trametinib by Cohort
Table Safety 3.1210 Summary of Serious Adverse Events by Cohort
Table Safety 3.1220 Summary of Serious Adverse Events By Maximum Grade and
Cohort
Table Safety 3.1310 Summary of Serious Adverse Events Related to Dabrafenib by 
Cohort
55CONFIDENTIA L
BRF117277
Table Safety 3.1311 Summary of Serious Adverse Events Related to Trametinib by 
Cohort
Table Safety 3.1410 Summary of Fatal Adverse Events by Cohort
Table Safety 3.1420 Summary of Fatal Adverse Events Related to Dabrafenib by 
Cohort
Table Safety 3.1421 Summary of Fatal Adverse Events Related to Trametinib by Cohort
Table Safety 3.1510 Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment by Cohort
Table Safety 3.1520 Summary of Adverse Events Leading to Dose Reductions by 
Cohort
Table Safety 3.1530 Summary of Adverse Events Leading to Dose Interruptions by 
Cohort
Table Safety 3.1600 Adverse Events of Special Interest Overview by Cohort
Table Safety 3.1610 Summary of Characteristics of Non -Cutaneous Treatment 
Emergent Malignancies
Table Safety 3.1611 Summary of Onset of the First Occurrence of Non -Cutaneous 
Treatment Emergent Malignancies
Table Safety 3.1613 Summary of Characteristics of New Primary Melanoma
Table Safety 3.1614 Summary of Onset of the First Occurrence of New Primary 
Melanoma
Table Safety 3.1616 Summary of Characteristics of Cutaneous Squamous Cell
Carcinoma including Keratoacanthoma
Table Safety 3.1617 Summary of Onset of the First Occurrence of Cutaneous 
Squamous Cell Carcinoma including Keratoacanthoma
Table Safety 3.1619 Summary of Characteristics of Cardiac Related Events
Table Safety 3.1620 Summary of Onset and Duration of the First Occurrence of Cardiac 
Related Events
Table Safety 3.1622 Summary of Characteristics of Hypertension
Table Safety 3.1623 Summary of Onset and Duration of the First Occurrence of 
Hypertension
Table Safety 3.1625 Summary of Characteristics of Diarrhea
Table Safety 3.1626 Summary of Onset and Duration of the First Occurrence of 
Diarrhea
Table Safety 3.1628 Summary of Characteristics of Ocular Events
Table Safety 3.1629 Summary of Onset and Duration of the First Occurrence of Ocular
Events
Table Safety 3.1631 Summary of Characteristics of Pneumonitis/Interstitial lung disease
56CONFIDENTIA L
BRF117277
Table Safety 3.1632 Summary of Onset and Duration of the First Occurrence of 
Pneumonitis/Interstitial lung disease
Table Safety 3.1634 Summary of Characteristics of Skin -Related Toxicities
Table Safety 3.1635 Summary of Onset and Duration of the First Occurrence of Skin -
Related Toxicities
Table Safety 3.1637 Summary of Characteristics of Neutropenia
Table Safety 3.1638 Summary of Onset and Duration of the First Occurrence of 
Neutropenia
Table Safety 3.1640 Summary of Characteristics of Uveitis
Table Safety 3.1641 Summary of Onset and Duration of the First Occurrence of Uveitis
Table Safety 3.1643 Summary of Characteristics of Deep Vein Thrombosis/Pulmonary 
Embolism
Table Safety 3.1644 Summary of Onset and Duration of the First Occurrence of Deep 
Vein Thrombosis/Pulmonary Embolism
Table Safety 3.1646 Summary of Characteristics of Edema
Table Safety 3.1647 Summary of Onset and Duration oftheFirst Occurrence ofEdema
Table Safety 3.1649 Summary of Characteristics of Pre-renal andIntrinsic Renal
Failure
Table Safety 3.1650 Summary of Onset and Duration of the First Occurrence of Pre-
renal and Intrinsic Renal Failure
Table Safety 3.1652 Summary of Characteristics of Hepatic Disorders
Table Safety 3.1653 Summary of Onset and Duration of the First Occurrence of Hepatic 
Disorders
Table Safety 3.1655 Summary of Characteristics of Pyrexia
Table Safety 3.1656 Summary of Onset and Duration oftheFirst Occurrence ofPyrexia
Table Safety 3.1658 Summary of Characteristics of Pancreatitis
Table Safety 3.1659 Summary of Onset and Duration of the First Occurrence of 
Pancreatitis
Table Safety 3.1661 Summary of Characteristics of Hyperglycemia
Table Safety 3.1662 Summary of Onset and Duration of the First Occurrence of 
Hyperglycemia
Table Safety 3.1664 Summary of Characteristics of Hypersensitivity
Table Safety 3.1665 Summary of Onset and Duration of the First Occurrence of 
Hypersensitivity
57CONFIDENTIA L
BRF117277
Table Safety 3.1667 Summary of Characteristics of Bleeding Events
Table Safety 3.1668 Summary of Onset and Duration of the First Occurrence of 
Bleeding Events
Table Safety 3.2010 Summary of Deaths by Cohort
Table Safety 3.3010 Summary of Chemistry Values by Cohort
Table Safety 3.3011 Summary of Haematology Values by Cohort
Table Safety 3.3012 Summary of Liver Function Test Values by Cohort
Table Safety 3.3013 Summary of Baseline Coagulation Test Values by Cohort
Table Safety 3.3020 Summary of Chemistry Grade Changes from Baseline Grade
Table Safety 3.3021 Summary of Hematology Grade Changes from Baseline Grade by 
Cohort
Table Safety 3.3022 Summary of Liver Function Test Grade Changes from Baseline 
Grade by Cohort
Table Safety 3.3030 Summary of Chemistry Changes from Baseline With Respect to 
the Normal Range
Table Safety 3.3031 Summary of Hematology Changes from Baseline With Respect to 
the Normal Range
Table Safety 3.3032 Summary of Liver Function Test Changes from Baseline With 
Respect totheNormal Range
Table Safety 3.4010 Summary of Vital Signs by Cohort
Table Safety 3.4020 Summary of Vital Sign Changes from Baseline by Cohort
Table Safety 3.4030 Summary of Changes in Heart Rate from Baseline by Cohort
Table Safety 3.4040 Summary of Increases in Systolic Blood Pressure from Baseline by
Cohort
Table Safety 3.4041 Summary of Increases in Diastolic Blood Pressure from Baseline 
by Cohort
Table Safety 3.4090 Summary of Left Ventricular Ejection Fraction Change from 
Baseline by Cohort
Table Safety 3.4110 Summary of ECOG performance Status byCohort
Table Safety 3.4120 Summary of Change in ECOG Performance Status from Baseline 
by Cohort
Table Safety 3.6010 Summary of ECG Findings by Cohort
Table Safety 3.6030 Summary of Increases inQTc (Bazett's) from Baseline byCohort
58CONFIDENTIA L
BRF117277
Table Safety 3.6040 Summary of Amount of Increase from Baseline Value in QTc 
(Bazett's) by Cohort
Table Safety 3.6050 Summary of QTc (Bazett's) Shifts from Baseline Value by Cohort
Table Safety 3.8010 Summary of Liver Chemistry Assessments for Subjects with Liver
Signal/Event by Cohort
Table Safety 3.8020 Summary of Hepatobiliary Laboratory Abnormalities by Cohort
Table Safety 3.8030 Summary of Liver Event Information for RUCAM Score by Cohort
Table Safety 3.9010 Summary of Ophthalmic Examinations by Cohort
Figure Efficacy 12.0010 Graph of Kaplan Meier Investigator -Assessed Progression Free
Survival Curve by Cohort
Figure Efficacy 12.0020 Graph of Kaplan Meier Investigator -Assessed Duration of
Intracranial Response Curve by Cohort
Figure Efficacy 12.0021 Graph of Kaplan Meier Investigator -Assessed Duration of
Extracranial Response Curve by Cohort
Figure Efficacy 12.0022 Graph of Kaplan Meier Investigator -Assessed Duration of Overall
Response Curve by Cohort
Figure Efficacy 12.0011 Graph of Kaplan Meier Independent Reviewer -Assessed
Progression Free Survival Curve by Cohort
Figure Efficacy 12.0023 Graph of Kaplan Meier Independent Reviewer -Assessed Duration
of Intracranial Response Curve by Cohort
Figure Efficacy 12.0024 Graph of Kaplan Meier Independent Reviewer -Assessed Duration
of Extracranial Response Curve by Cohort
Figure Efficacy 12.0025 Graph of Kaplan Meier Independent Reviewer -Assessed Duration
of Overall Response Curve by Cohort
Figure Efficacy 12.0030 Graph of Kaplan Meier Overall Survival Curves by Cohort
Figure Efficacy 12.0040 Investigator -Assessed Percent Change atMaximum Reduction
from Baseline in Intracranial Tumour Measurement by Cohort
Figure Efficacy 12.0041 Independent Reviewer -Assessed Percent Change at Maximum
Reduction from Baseline in Intracranial Tumour Measurement by
Cohort
Figure Safety 12.0050 QTc (Bazett's) Shifts from Baseline to Worst -case Post Baseline
by Cohort
Figure Safety 12.0060 Figure of LFT Patient Profiles forPossible Hy’s Law Subjects by
Cohort
Figure Safety 12.0070 Figure of Maximum Total Bilirubin vs Maximum ALT by Cohort –
eDISH Plot
Listing Study
Pop21.0010 Listing of Planned and Actual Treatments
Listing Study
Pop21.0020 Listing of Subjects Excluded from Analysis Population
Listing Study
Pop21.0030 Listing of Reasons for Study Withdrawal
59CONFIDENTIA L
BRF117277
21.0040 Listing of Dabrafenib Discontinuation Record
21.0041 Listing of Trametinib Discontinuation Record
21.0050 Listing of Subjects with Inclusion/Exclusion Criteria Deviations
21.0060 Listing of Protocol Deviations
21.0070 Listing of Demographic Characteristics
21.0080 Listing of Race
21.0090 Listing of Overall Compliance (Dabrafenib)
21.0091 Listing of Overall Compliance (Tramatinib)
21.0100 Listing of Drug Accountability (Dabrafenib)
21.0101 Listing of Drug Accountability (Tramatinib)
22.0010 Listing of Investigator -Assessed Progression -Free Surviva l
22.0011 Listing of Independent Reviewer -Assessed Progression -Free
Survival
22.0020 Listing of Overall Survival
22.0030 Listing of Investigator -Assessed Duration of Response
22.0031 Listing of Independent Reviewer -Assessed Duration of Response
22.0040 Listing of Investigator -Assessed Target Lesion Assessments
(modified RECIST 1.1 Criteria)
22.0050 Listing of Investigator. -Assessed Non-Target Lesion Assessments
(modified RECIST 1.1 Criteria)
22.0060 Listing of Investigator -Assessed New Lesions (modified RECIST
1.1 Criteria)
22.0041 Listing of Independent Reviewer -Assessed Target Lesion
Assessments (modified RECIST 1.1 Criteria)
22.0051 Listing of Independent Reviewer -Assessed Non-Target Lesion
Assessments (modified RECIST 1.1 Criteria)
22.0061 Listing of Independent Reviewer -Assessed New Lesions (modified
RECIST 1.1 Criteria)
22.0070 Listing of Investigator -Assessed Tumour Responses (with
confirmation) (modified RECIST1.1 Criteria)
22.0071 Listing of Independent Reviewer. -Assessed Tumour Respons es
(with confirmation) (modified RECIST1.1 Criteria)Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
Listing Efficacy
60CONFIDENTIA L
BRF117277
23.0010 Listing of Exposure to Dabrafenib
23.0011 Listing of Exposure to Trametinib
23.0020 Listing of Dose Reductions of Dabrafenib
23.0021 Listing of Dose Reductions of Trametinib
23.0030 Listing of Dose Interruptions of Dabrafenib
23.0031 Listing of Dose Interruptions of Trametinib
23.0090 Listing of Relationship Between System Organ Class, Preferred
Term, and Verbatim Text
23.0100 Listing of Subject Numbers for Individual Adverse Events
23.0110 Listing ofAllAdverse Events
23.0120 Listing of Fatal Serious Adverse Events
23.0130 Listing of Non -Fatal Serious Adverse Events
23.0140 Listing of Adverse Events Leading to Permanent Discontinuation of
Dabrafenib
23.0141 Listing of Adverse Events Leading to Permanent Discontinuation of
Trametinib
23.0150 Listing of Adverse Events that Lead to Dose Interruptions of
Dabrafenib
23.0151 Listing of Adverse Events that Lead to Dose Interruptions of
Trametinib
23.0200 Listing of Non-Cutaneous Treatment Emergent Malignancies
23.0201 Listing of Cardiac -Related Events
23.0202 Listing of Hypertension
23.0203 Listing of Diar rhea
23.0204 Listing of Ocular Events
23.0205 Listing of Pneumonitis/Interstitial lung disease
23.0206 Listing of Skin-Related Toxicities
23.0207 Listing of NeutropeniaListing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
61CONFIDENTIA L
BRF117277
23.0208 Listing of Uveitis
23.0209 Listing of Deep Vein Thrombosis/Pulmonary Embolism
23.0210 Listing of Edema
23.0211 Listing of Pre-renal and Intrinsic Renal Failure
23.0212 Listing of Hepatic Disorders
23.0213 Listing of New Primary Melanoma
23.0214 Listing of Cutaneous Squamous Cell Carcinoma including
Keratoacanthoma
23.0215 Listing of Pyrexia
23.0216 Listing of Pancreatitis
23.0217 Listing of Hyperglycemia
23.0218 Listing of Hypersensitivity
23.0219 Listing of Bleeding Events
23.0250 Listing of Deaths
23.0260 Listing of All Laboratory Data
23.0270 Listing of Laboratory Data for Subjects with Lab Values Outside of
Normal Range
23.0280 Listing of ECOG Performance Status
30.0010 Listing of Tobacco Use
30.0011 Listing of Alcohol Consumption
30.0020 Listing of Past Medical Conditions
30.0021 Listing of Current Cancer -Related Medical Conditions
30.0030 Listing of Disease Characteristics at Initial Diagnosis
30.0040 Listing of Disease Characteristics at Screening
30.0050 Listing of Prior Anti-Cancer TherapyListing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Study
Pop
62CONFIDENTIA L
BRF117277
30.0060 Listing of Prior Anti-Cancer Radiotherapy
30.0070 Listing of Prior Cancer -Cancer Related Surgical Procedures
30.0090 Listing of Concomitant Medications
30.0130 Listing of Subjects with a Difference between Investigator-
Assessed and Independent Reviewer- Assessed Tumour
Response (with confirmation) (modified RECIST 1.1 Criteria)
30.0140 Listing of Subjects with a Difference between Investigator-
Assessed and Independent Reviewer- Assessed Best Tumor
Response
30.0220 Listing of Subject Numbers for Specific Causes of Deaths
30.0240 Listing of Abnormal ECG Findings
30.0250 Listing of ECG Values
30.0270 Listing of Vital Signs
30.0280 Listing of Left Ventricular Ejection Fraction Results
30.0290 Listing of Liver Chemistry Assessments for Subjects with Liver
Signal/Events
30.0300 Listing of Liver Laboratory Tests and Grade
30.0330 Listing of Ophthalmic Examinations
14.1.1. Data Display Deliv erables
All display sin Section 14.1 will be provided at the time of the primary endpoint analy sis.
The following display sfrom Section 14.1 will be provided for the interim analy sis:
Table
No. Title
1.0010 Summary of Study Populations by Cohort
1.1110 Summary of Subject Disposition by Cohort
1.1220 Summary of Study Treatment Status ForTrametinib by CohortListing Study
Pop
Listing Study
Pop
Listing Study
Pop
Listing Efficacy
Listing Efficacy
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety
Listing Safety

63CONFIDENTIA L
BRF117277
1.1221 Summary of Study Treatment Status For Dabrafenib by Cohort
1.2010 Summary of Demographic Characteristics by Cohort
1.2110 Summary of Extracranial Disease Burden at Baseline by Cohort 
1.3220 Summary of Disease Characteristics at Screening By Cohort 
1.4020 Summary of Prior Dictionary Coded Anti-Cancer Therapy by Cohort
1.4030 Summary of Number of Prior Anti-Cancer Therapy Regimens byCohort
1.5010 Summary of Concomitant Medications by Cohort
2.1009 Investigator -Assessed Best Intracranial Response (with confirmation) (modified
RECIST 1.1 Criteria) for Cohort A (Interim Analysis)
2.1010 Investigator -Assessed Best Intracranial Response (with confirmation) (modified
RECIST 1.1 Criteria) for Cohort A (Primary Analysis)
2.1011 Investigator -Assessed Best Intracranial Response (with confirmation) (modified
RECIST 1.1 Criteria) for Cohorts B, C, and D
2.1012 Investigator -Assessed Best Extracranial Response (with confirmation) (modified
RECIST 1.1 Criteria) by Cohort
2.1013 Investigator -Assessed Best Overall Response (with confirmation) (modified RECIST
1.1 Criteria) by Cohort
3.0010      Summary of Exposure to Dabrafenib byCohort 
3.0011       Summary of Exposure to Trametinib by Cohort 
3.1010      Adverse Event Overview by Cohort
3.1070 Summar y of Adverse Events By Maximum Grade by Cohort
3.1090 Summary of Adverse Events of Special Interest by Maximum Grade and Cohort 
3.1110 Summary of Adverse Events Related to Dabrafenib by Cohort
3.1111 Summary of Adverse Events Related to Trametinib by Coho rt 
3.1210 Summary of Serious Adverse Events by Cohort
3.1410 Summary of Fatal Adverse Events by Cohort
3.1510 Summary of Adverse Events Leading to Permanent Discontinuation of Study 
Treatment by Cohort
3.1520 Summary of Adverse Events Leading to Dose Reductions by Cohort
64CONFIDENTIA L
BRF117277
3.1530 Summary of Adverse Events Leading to Dose Interruptions by Cohort 
3.1600 Adverse Events of Special Interest Overview by Cohort
3.2010 Summary of Deaths by Cohort
3.3020 Summary of Chemistry Grade Changes from Baseline Grade
3.3021 Summary of Hematology Grade Changes from Baseline Grade by Cohort
3.3020 Summary of Liver Function Test Grade Changes from Baseline Grade byCohort 
3.3030 Summary of Chemistry Changes from Baseline With Respect to the Normal Range 
3.3031 Summary of Hematology Changes from Baseline With Respect to the Normal Range 
3.3032 Summary of Liver Function Test Changes from Baseline With Respect to the Normal
Range
3.4020 Summary of Vital Sign Changes from Baseline by Cohort
3.4040 Summary of Increases in Systolic Blood Pressure from Baseline by Cohort 
3.4090 Summary of Left Ventricular Ejection Fraction Change from Baseline by Cohort
3.6010 Summary of ECG Findings by Cohort
3.6030 Summary of Increases in QTc (Bazett's) by Cohort
3.6040 Summar y of Amount of Increase from Baseline Value in QTc (Bazett's) by Cohort 
3.6050 Summary of QTc (Bazett's) Shifts from Baseline Value by Cohort
3.8010 Summary of Liver Chemistry Assessments for Subjects with Liver Signal/Event 
by Cohort
3.8020 Summary of Hepatobiliary Laboratory Abnormalities by Cohort 
3.8030 Summary of Liver Event Information for RUCAM Score by Cohort
The display sfor the End of Study analy siswill be provided in a separate TFL document :
14.2. Data Display Specifications
The data display specifications are contained in a separate document. The display mock-
ups are provided as a guideline. The final formats andlayouts may be revised due to
potential limitations of the programs and tools used to produce the display s.